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ABSTRACT
Cognitive frailty is considered a potentially reversible age-related condition
characterized by the simultaneous presence of both physical frailty and cognitive
decline. The concept of cognitive frailty existing in older adults is indisputable, although
the mechanisms and the directional relationship behind the dynamic association remain
unexplained. Mechanisms have been suggested, often linking cognitive frailty to
cognitive impairment or as a component of frailty but without an understanding of the
biological bases for these associations we cannot not move forward with intervention
trials.
This dissertation examines the biological mechanisms for cognitive frailty. The study is
the first to use a large number of protein and genetic markers identified by a systematic
review to define the underlying pathology for cognitive frailty. We use an innovative
Boosted trees machine learning technique for developing a population based predictive
model. Xgboost is based in boosted trees and provides more efficient and accurate
predictive modeling with large datasets and a rapid / robust framework for feature
selection. Statistical modeling is used to design, test, and validate an accurate method
for and identifying and classifying the features that predict individuals with cognitive
frailty. The tree boosting model is used for the evaluation of multiple variables
simultaneously and provides a high predictive value with low bias.
The results presented within this dissertation create a foundation of understanding
for a new aging condition and encourage translational research focused on the
detection and prevention of cognitive frailty.
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INTRODUCTION
“I forget what I was trying to say, one word or another gets in the way of the word I
meant to use. Nothing stays. So I say something else, I compensate….are these the
words I meant to say? But wait, are these the words I meant to say? These words
migrate, they refuse to stay in place. This is my new life, my new way, I forget what I
was trying to say.” Sherman Alexie.
Caregivers of patients with cognitive decline and patients themselves will suggest
that their symptoms for memory loss and changes in physical function came long before
they received a diagnosis by their provider. A report on the economic implications of
cognitive decline estimates in 2015 there are 5.1 million individuals(1,2). With the aging
“baby boomer” generation the trajectory that individuals will exhibit cognitive decline
will be 13.5 million by the year 2050 in the United States(1,2). Efforts to unravel the
mechanisms for cognitive decline have led to the recognition of a unique cluster of
individuals who present with the simultaneous presences of both physical frailty and
cognitive impairment without dementia(3). Both cognitive decline and physical frailty
independently lead to increased disability, falls, mortality, an increase in health service
need, and high direct/indirect costs to healthcare, often long-term care and
hospitalization(4,5). Individuals with physical frailty and cognitive impairment may have
a higher risk for disability than individuals with isolated physical frailty or cognitive
impairment. Yet, historically, most research groups have excluded older adults with
cognitive impairment from frailty studies(4). The International Consensus Group
organized by the International Academy on Nutrition and Aging (I.A.N.A) and the
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International Association of Gerontology and Geriatrics (I.A.G.G) convened in 2013 to
identify related domains of physical frailty and cognition and termed the phenomenon
“cognitive frailty”(3).
Establishing a model to detect cognitive frailty
The Institute of Medicine Report on Cognitive Aging described a need to develop an
operational definition of cognitive frailty for use in research, clinical detection, and
public health surveillance(6). A model for detecting cognitive frailty could provide
practitioners with the tools needed for early detection and secondary prevention.
Currently, the instrumental assessments for cognitive frailty are time-consuming,
expensive, and require extensive training, and the clinical translation properties are not
clear(3). The translation of the cognitive frailty construct into the clinical setting is
limited by the lack of consensus on an operational definition and considerable
heterogeneity and complexity in the diagnostic criteria. The primary purpose of this
research was to create a population predictive model to gain a more in-depth
understanding of the underlying biological mechanisms for cognitive frailty as currently
defined by the International Consensus Group in 2013. This dissertation focuses on
defining the shared mechanisms for physical frailty and cognitive impairment and
establishing a model for determining the presence of risk factors that may predict
cognitive frailty in the clinical setting. The model will advance the development of an
operational definition by determining whether the potential risk factors at present may
predict cognitive frailty in the clinical setting.
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Mechanisms behind cognitive frailty
The mechanisms and the directional relationship behind the dynamic association of
physical frailty and cognitive impairment or cognitive frailty remain unexplained.
Pathological events leading to cognitive frailty years before the onset of cognitive
decline may be marked by epigenetic modifications that influence memory-associated
gene transcription. However, to date, no investigators have simultaneously
characterized the trajectory of cognitive decline and physical function, underlying
cellular events that include physiological factors, and epigenetic modifications. The
results presented here will further explicate the shared mechanisms, including putative
biomarkers for physical frailty and cognitive impairment to enhance our understanding
of the shared neuropathology in a secondary data analysis. Such an understanding will
lead to intervention studies focused on preventing disability and mortality, decreasing
health service use, and improving health outcomes for older adults.
OPERATIONAL DEFINTIONS
The extent to which we can predict cognitive frailty using biomarkers depends on the
accuracy that our behavioral markers have on early identification. Screening for the
detection of cognitive decline (i.e. neuropsychological) and frailty is determined by the
identification tools for defining individuals with cognitive frailty. Individuals with
cognitive frailty present with a unique neuropsychological profile, scoring worse on
executive and attention tests with individuals having 3 or more of the frailty criteria
being more impaired than individuals with only 1 of the frailty criteria(7). This
dissertation focused on markers for early detection therefore, definitions used to
4

establish phenotype sub-groups in this study were structured to detect early cognitive
decline including pre-frail individuals using neuropsychological testing focused on
executive and attention memory domains. The definitions used are as follows:
Cognitive decline – mild neurocognitive disorders
Evidence of modest cognitive decline from a previous level of performance in one or
more cognitive domains (complex attention, executive function, learning and memory,
language, perceptual motor, or social cognition) with a modest impairment in cognitive
performance by standardized neuropsychological testing or clinical assessment in
absence of a diagnosis of dementia(8,9).
Frailty
The operational definition for frailty is defined as a clinical syndrome condition including
3 out of the 5 criteria related a physical phenotype including: 1) weak muscle strength
(grip strength), 2) slow gait speed, 3) unintentional weight loss, 4) exhaustion and low
physical activity(4). Pre-frailty includes 1 or 2 of the criteria is present, identifying a subgroup of individuals potentially progressing to frailty(4).
Cognitive frailty
The International Consensus Group (I.A.N.A. /I.A.G.G.) report is an acknowledgment of
the need to focus research efforts on a clinical condition characterized by the cooccurrence of physical frailty and cognitive impairment, in absence of overt dementia
diagnosis or underlying neurological conditions(3). The cognitive frailty construct is
considered a heterogeneous clinical syndrome in older adults with evidence of: 1)
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physical frailty and cognitive impairment (Clinical Dementia Rating score of 0.5); and 2)
exclusion of a clinical diagnosis of Alzheimer’s Disease or other dementia(3).
Details on the cut-off scores used to define the phenotypes are explained in further
detail in manuscripts 3 and 4.
INNOVATION
An important innovation in this study was the use of machine learning (ML) statistical
modeling to build a predictive model for cognitive frailty while further defining the
unique features for cognitive decline and frailty. We use Boosted trees, a machine
learning technique for supervised learning, these are ensembles of regression trees,
similar to decision trees and are used for prediction or classification. Xgboost is based in
boosted trees and provides more efficient and accurate predictive modeling with large
datasets and a rapid / robust framework for feature selection. Statistical modeling is
used to design, test, and validate an accurate method for classifying patients into
phenotypic outcomes. The tree boosting model for the evaluation of multiple variables
simultaneously provides a high predictive value with low bias. The second innovation in
this study is the defining of putative biomarkers related to cognitive frailty leading to a
better understanding of the interrelated neuropathology between physical frailty and
cognitive impairment. The study is the first to use a large number of protein and genetic
markers (n=289) identified by a systematic review to define the underlying pathology for
cognitive frailty.
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Impact of Proposed Research
Developing and validating a model for the detection and classification of cognitive
frailty will improve the ability to detect patients with a potentially reversible cognitive
and physical decline. Identification of biomarkers and an understanding of the
physiological and genetic factors for cognitive frailty will help distinguish between
changes related to normal aging, irreversible pathological process, and specific
neurological diseases that may be reversible(6). The findings will encourage new
research and may lead to effective interventions for the prevention and treatment of
cognitive and physical decline in an aging population.
THEORETICAL FRAMEWORK
This dissertation used Complex Systems Theory as a primary theoretical framework.
Complex Systems Theory (CTS) is an approach to science that involves multiple factors
that interact nonlinearly to form a dynamic set of relationships leading to physiological
change(10). Based in the tradition of ontology, CTS can identify the grouping together of
the mechanistic elements of biology and the heuristic elements of philosophy to model
the linkages that create a complex concept such as cognitive frailty. Biological
mechanisms, proteins or gene expression and their patterns of interaction are
inherently complex systems about which numerous empirical data exist (in this case
within population databases) that are “dynamic and transformational” vs. inductive
assumptions (11,12). Computational methods developed in bioinformatics are uniquely
designed to analyze and interpret large amounts of biological data. This dissertation
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created a theoretical framework based on the modeling of complex systems using
bioinformatics (figure 1).
SPECIFIC AIMS
This dissertation consists of four manuscripts; 1) an integrative review assessing the
measurement properties for cognitive frailty, 2) a systematic review exploring the
biological factors for cognitive frailty, 3) a population based modeling study establishing
biological plausibility for cognitive frailty, and 4) additional analysis of a unique feature
from the modeling study and potential epigenetic factor for cognitive frailty;
anticholinergic burden’s association with cognitive decline, physical frailty, and cognitive
frailty.
Aim 1. To determine associations between putative biomarkers and cognitive frailty as
currently defined by the International Consensus Group in 2013 using a focused
secondary analysis of the InCHIANTI study dataset.
1a. Establish a predictive model using statistical methodologies using an integrative
approach to precisely define and predict cognitive frailty based on overlapping risk
factors for frailty and cognitive decline.
1b. Establish a relationship among measurable physiological, clinical factors, and the
development of cognitive frailty.
1c. Establish associations between physical frailty and cognitive parameters (i.e., losses
in specific types of memory and mental acuity).
Manuscript 1 includes a comprehensive review of the measurement tools for
defining the phenotype cognitive frailty. Manuscript 2 includes a large systematic review
8

of the potential putative clinical, protein, and genetic biomarkers for cognitive frailty.
The markers identified in this comprehensive review were used as predictors in the
population modeling study. Manuscripts 3, is the population based predictive model
analysis. Findings from the model study resulted in anticholinergic burden as a unique
predictor of cognitive decline, frailty, and cognitive frailty. Considering anticholinergic
medication burden could be a potentially reversible cause for cognitive frailty additional
analyses was completed which resulted in manuscript 4.
Aim 2. To determine associations between genetic biomarkers; single-nucleotide polymorphisms (SNPs) to explain the phenotypic variance for cognitive frailty using a focused
secondary analysis of the InCHIANTI study dataset.
Manuscript 3 includes analyses of genetic biomarkers (SNPs) and highlights the variance
seen for individuals with cognitive frailty compared to unique genetic predictors of
cognitive decline and frailty alone.
Training Aim3. Acquire the necessary training, expertise, and knowledge to accomplish
aims 1 and 2. Goal 1: Apply advanced statistical methods; Goal 2: Develop
neuropsychiatric assessment skills.
Due to the innovative statistical modeling and bioinformatics utilized in this dissertation,
additional training was needed beyond the standard Doctoral in Philosophy in Nursing
Science curriculum to build knowledge and achieve stated aims. I completed the
bioinformatics 101 seminar series which included training on: high-throughput
technology, high-throughput sequencing data types and public data repositories, DNA
and RNA-seq applications and analyses, ChIP-seq applications and analyses, and
9

pathway and functional enrichment analysis methods. The bioinformatics certificate is
included in the supplemental documents. Additionally, I attended conference training
on Health Measures, which included training on the NIH neurophysiological, and
physical measures toolbox and Patient-Reported Outcomes Measurement Information
Systems (PROMIS) measures.
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Figure1. Complex systems theory for Cognitive Frailty
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MANUSCRIPT 1:

Assessing the Current State of Cognitive Frailty: Measurement Properties
This manuscript was accepted for publication in the international journal Nutritional
Health and Aging (reprinted with permission). Sargent, L., & Brown, R. Assessing the
Current State of Cognitive Frailty: Measurement Properties. Journal of Nutrition Health
and Aging. January 2017, Vol 21, Issue 1.
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MANUSCRIPT 2:

Determining Biological Factors for Cognitive Frailty: A Systematic Review
Abstract: On April 16th, 2013 the International Consensus Group (I.A.N.A/I.A.G.G)
formally defined the novel phenotype cognitive frailty; a condition characterized by the
co-occurrence of physical frailty and cognitive impairment. We hypothesize that there
are biological factors to describe the interconnection between physical frailty and
cognitive impairment. This systematic review focuses on identifying the shared
measurable biological and genomic mechanisms for physical frailty and cognitive
decline. Two independent reviewers assessed the eligibility of each report based on
predefined inclusion criteria to ensure interrater reliability; a third reviewer resolved
conflicting assessments. The review was conducted using PubMed, Embase, Scopus,
Web of Science, LILACS, Gene Indexer, and GWAS Central. Findings resulted in 1232
abstracts for full review, 327 articles were included in the final review. Data extraction
identified a correlation between 16 distinct inflammatory and protein markers with
biomarker-related gene expression for cognitive frailty. Meaningful findings were
identified in the relationship between protein and genetic markers found for both
cognitive decline and physical frailty. This systematic review presence the first known
findings of the underlying biological characteristics for cognitive frailty providing
evidence for converging pathophysiological pathways.
Introduction
In the past century, scientific research has been driven by molecular science with the
common goal of identifying a single group of biological or genetic mechanisms as the
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cause of disease. We now understand that the mechanisms underlying disease
processes are multi-factorial and system based. A multi-system physiological disease
requires a systems approach to precision research especially with older adults who have
variable trajectories to the aging process with multiple co-morbidities. Efforts to unravel
this complexity start with understanding the unique biological factors for a cluster of
individuals presenting with similar symptoms and trajectories. Cognitive frailty can be
considered a unique geriatric phenomenon in which we see a cluster of individuals with
a condition which simultaneously presents with both physical frailty and cognitive
impairment1. The International Consensus Group organized by the International
Academy on Nutrition and Aging (I.A.N.A) and the International Association of
Gerontology and Geriatrics (I.A.G.G) convened in 2013 to identify related domains of
physical frailty and cognition. The new construct called “cognitive frailty” is defined by
the presence of physical frailty and cognitive impairment in the absence of Alzheimer’s
disease or other dementias1. The mechanisms and the directional relationship behind
the dynamic association of these two constructs remains unexplained. There exists
strong evidence for the association of frailty and cognitive decline with suggestion for
pathophysiological mechanisms which are shared by both clinical manifestations2.
Although, some research has been conducted on the association between physical
function and cognitive decline there is still no comprehensive list or understanding of
the underlying mechanisms for cognitive frailty. Therefore, to further develop an
understanding of cognitive frailty, it is critical that the operational definition explore
both clinical and biological markers for cognitive decline and physical frailty.
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Identification of a measurable cellular, biochemical, or molecular markers for
cognitive frailty has not been identified. Because both cognitive decline and physical
frailty are large heterogeneous conditions it may not be possible to identify one
biomarker to measure both cognitive decline and frailty. The use of one or more
biomarkers specific to both constructs will improve our understanding of the
association3,4. It is possible that the underlying biological mechanisms for cognitive
frailty are at the intersect between cognitive decline and physical frailty or cognitive
frailty may contain some of its own unique markers of disease.
Some evidence exists to support inflammatory biomarkers (neuroinflammatory
cytokines) such as C-reactive protein (CRP) and Interleukin-6 (IL-6) as antecedent
biomarkers since they are associated with frailty and cognitive decline1,3. The
complicated use of inflammatory biomarkers, such as CRP, for detection of disease is
that they can be detected in other co-morbid diseases found in older adults (i.e.
cardiovascular disease, rheumatologic disease). Wilson, Finch, and Cohen (2002)
completed a review exploring over 30 neuroinflammatory cytokines and their findings
indicate the potential for detection of cognitive decline and evidence for associated
improvement of cognition with targeted interventions to reduce the production of
specific neuroinflammatory cytokine markers5. Finally, genetic factors associated with
cognitive frailty have not been fully explored. There have been several genome-wide
association studies (GWAS) and candidate gene studies for cognitive decline with only
more recent studies exploring the genetic mechanisms for frailty.
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Methods
Search strategy
In this review, we followed the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines6. A systematic review of the literature was
performed using the following online databases: PubMed, Embase, Scopus, Web of
Science, LILACS, Gene Indexer, and GWAS Central. For reproducibility, we have provided
the PubMed search strategy in the supplementary appendix (Figure I). Databases were
searched from the start date of the database to 22 December, 2015. An update of the
searches was performed prior to the data extraction phase on 26 May, 2016 to identify
any new publications. In addition to database searching, articles were hand-pulled from
references and identified through other sources.
Inclusion and exclusion criteria
Studies that included information on biomarkers or genetic markers for dementia,
physical frailty, or cognitive frailty were included. Reviews, animal studies, imaging
biomarkers, and case studies were excluded. Studies on a geriatric population, aged 65
and older, were included. Articles about other disease states such as cancer, Multiple
Sclerosis, Down syndrome, Parkinson’s disease, human immunodeficiency virus (HIV),
and Huntingdon’s disease were excluded. Articles published in English were included.
Study appraisals
A multi-step approach was used to evaluate relevant articles using Covidence, a webbased software platform selected by Cochrane Reviews that organizes and streamlines
the systematic review process7. Figure I shows the stages (PRISMA) for retrieving the
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studies for inclusion and extraction. We conducted a review of the titles and abstracts of
all the papers identified through database searching and hand pulling from references
lists. Three reviewers participated in this step and each article was reviewed by two
reviewers (LS and AS) to ensure interrater reliability. A third reviewer (SH) resolved
conflicting assessments. A fourth reviewer (EA) was available for additional arbitration
however their services were not required. From 5942 articles identified, titles and/or
abstracts reporting on information pertaining to biomarkers or genetic markers for
cognitive decline, physical frailty, or cognitive frailty was included. 1232 potential
relevant articles were chosen for closer review, two reviewers with appropriate subject
expertise (LS and AS) assessed the full-text of the articles for relevancy. 327 full-text
articles reporting on the relevant topic met inclusion/exclusion criteria and 899 articles
were excluded. Reviewer disagreements were addressed in regular meetings and
resolved. A final 327 articles were included in this systematic review.
Extraction
The analysis for this paper was generated using Qualtrics software, Version 9.2017 of
Qualtric (Copyright © [2017] Qualtrics. Qualtrics and all other Qualtrics product or
service names are registered trademarks or trademarks of Qualtrics, Provo, UT, USA.
http://www.qualtrics.com.) The survey created in Qualtrix (Qualtrics, Provo, UT)
ensured consistency in reporting of biological markers limiting open text boxes,
consistent categorizing of biomarkers by clinical, genetic, and fluid markers in the
following categories: inflammatory/immunity, protein, metabolomics, oxidative stress.
The database assigned each biomarker unique numeric code (i.e. IL6-3, CRP-27). When
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data entry was complete, the final data frame was exported from Qualtrix and an
analysis was carried out using R V. 3.2.1. R is free, open-source software that provides
many statistical and graphic techniques. R packages used included ‘MASS’ and
‘ggplot2’8,9.
We did not complete a formal method of assessment for the quality of the studies
with a meta-analysis given that the goal of this review is to identify potential putative
markers for a new phenotype “cognitive frailty”. Level of evidence was appraised for
longitudinal, observational (cohort, cross Sectional, case-control studies), and
randomized clinical trials (RCTs) using the Center for Evidence Based Medicine Levels of
Evidence10. Additionally, there are limited (RCTs) for frailty and none for cognitive
frailty. We do provide a compressive list of the principle results, study design, and detail
list of genetic findings correlated to one of the following phenotypes: cognitive decline,
frailty, and cognitive frailty. The markers extracted for correlation to cognitive frailty
were identified by the reviews to be studies that explored both frailty and cognitive
decline in the same study.
Findings and discussion
A total of 327 articles were used to extract the clinical, genetic, and protein markers for
three phenotypes: cognitive decline, physical frailty, and cognitive frailty. Date ranges
for the studies are shown in Figure II. Studies were reviewed in the following categories
39 genetic studies: 9 GWAS and 30 candidate gene studies, 279 biological protein
studies, 9 medication risk studies. Additional study designs included observational
(Cohort, cross sectional, and case-control studies), longitudinal, RCT and In Vitro studies.
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For the 13 studies that included both a longitudinal and observational (Cohort, cross
sectional, and case-control studies) study design we extracted markers from both study
designs. The studies were categorized by phenotype: cognitive decline (n= 243), frailty
(n= 72), and cognitive frailty (n= 11). Phenotypes were further defined by the type of
cognitive decline (i.e. Alzheimer’s disease, mild cognitive impairment) and component
of frailty (i.e. gait, sarcopenia, grip strength, physical activity) as stated in the study or a
combination both was considered cognitive frailty. The supplementary appendix (table
I) shows the clinical and biomarkers extracted from 288 articles. Tables I-III show the
biomarkers extracted by phenotype in the following categories: clinical,
inflammatory/immunity, laboratory, protein, metabolomics, and oxidative stress.
Additionally, a summation or frequency in which the biomarker occurred out of the 288
articles is shown by phenotype.
Clinical markers
Although, clinical markers were not a part of the search strategy several of the studies
reported clinical findings associated with cognitive decline, physical frailty, and cognitive
frailty. Demographics such as increasing age were a factor for all phenotypes, lower
education and income were factors for individuals with cognitive decline and frailty.
Other clinical markers included: measures of cardiovascular disease, elevated blood
pressure, multiple co-morbidities, changes in body mass index (BMI), and alcohol intake.
One of the most interesting clinical findings was an association between medications
and all phenotypes. These included hypertension, benzodiazepine, anticholinergic, and
psychoactive medications. Two categories of hypertensive medications beta-blockers
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(i.e. metoprolol and atenolol) and angiotensin-converting enzyme (ACE) inhibitors were
found to have the most significant effect on cognitive decline11,12. Additionally, there
was a significant interaction between ACE inhibitor use and carriers of ApoE4 (odds
ratio: 20.9, 95% CI 3.08-140.95, p= .002)12. Anticholinergic burden was found to be
associated with cognitive decline and physical frailty. An interaction was found between
ApoE4 carriers and anticholinergic medications with users having the lowest cognitive
scores. Irrespective of ApoE4 status, drugs with high anticholinergic properties were
associated with cognitive and physical decline11,13–16. Methods for measuring medication
burden varied significantly between studies making it difficult compare study results.
Inflammatory/Immunity markers
There were 16 neuroinflammatory cytokine markers associated with cognitive decline
and frailty. These included: elevated levels of IL6, CRP, tumor necrosis factor (TNFalpha), uric acid, IL1-beta, erythrocyte sedimentation rate (ESR),
cortisol/dehydroepiandrosterone ratio, IL1RA, CD8, IL6R, TNF-a receptor I (TNFR1),
cortisol, homocysteine, fibrinogen, and beta 2-microglobulin (B2M). Additionally, all the
neuroinflammatory markers associated with cognitive frailty were associated with
either cognitive decline or frailty. These neuroinflammatory cytokines were found to be
associated with cognitive decline and frailty in cross-sectional and longitudinal studies
suggesting that these markers could be both early and persistent markers. The presence
of the hypothalamic-pituitary-adrenal (HPA) axis hormones such as
dehydroepiandrosterone can interact with inflammatory markers to influence disease.
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This relationship should be explored further with clinical markers such as gender and
body mass index.
Laboratory markers
Twenty laboratory markers are associated with both phenotypes and include:
Nutritional markers: low levels of vitamin D, total albumin, and selenium;
Cardiovascular/endocrine markers: elevated total cholesterol, triglycerides, LDL, insulin
like growth factor protein (IGF-1), glucose, insulin resistance, HbA1c; Hematology/renal
markers: elevated creatinine, creatinine clearance, blood urea nitrogen (BUN), white
blood cells (WBC); and decreased hemoglobin, hematocrit, cobalamin deficiency (B12),
and increased methylmalonic acid (MMA), and hormonal marker: low levels of total
testosterone associated with decreased lean muscle mass and cognitive decline. These
markers combined with endocrine and immune markers suggest changes to the cellular
immune system and HPA axis that are related to cognitive and physical decline.
Additionally, several studies included these markers and the inflammatory/immune
markers as a composite score and found an increased risk for developing cognitive
decline, frailty, and mortality17–22.
Protein markers
Several of the protein markers were measured by cerebrospinal fluid (CSF) and included
known biomarkers associated with the neurofibrillary tangles involved in the
pathogenesis of neurodegenerative diseases such as Alzheimer’s disease and
frontotemporal dementia23. None of these markers (i.e. p-tau, Aβeta-42) have been
studied in frailty. Three markers measured by serum/plasma were associated with both
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cognitive decline and frailty, these included: sirtuin 1 and cystatin C. The down
regulation of Sirtuin 1 has been reported to be involved in the pathway that controls the
expression of Aβeta peptide through ADAM1024. Concentrations of sirtuin 1 decline with
age but the decline was found to be more significant in individuals with cognitive decline
and frailty compared to age matched healthy individuals24,25. Additionally, cystatin C
has been thought to bind to soluble Aβeta preventing accumulation in the brain26.
Decreased serum cystatin C has been associated with higher risk for cognitive decline
and gait speed decline27,28.
Metabolomics and oxidative stress markers
No metabolomics markers were found to be related to cognitive frailty. Two oxidative
stress markers were associated, these included: malondialdehyde (MDA) and protein
carbonyls. MDA and protein carbonyls are well established oxidative biomarkers and are
considered to be a good measure of systemic oxidative stress29. Both are associated
with frailty and cognitive decline but not predictive of the development or progression
of disease29,30.
Genetic
The supplementary appendix table II shows a complete list of genetic markers identified
by phenotype. Three genes were found to be associated with cognitive decline and
frailty in candidate gene studies: IL6 rs1800796, TNF rs1800629, and COMT with
different SNPs, rs4680 for cognitive decline and rs4646316 for frailty. IL6 and TNF have
corresponding serum markers that are associated with both phenotypes (see
inflammatory/immunity markers) 31–34.
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There are 12 serum biomarker and gene correlations, these are shown in table IV.
Further evaluation is need to determine if there is a direct correlation between gene
expression and serum marker function.
Conclusions
It has previously been postulated that a dysregulation across multiple systems may be
the potential cause for both cognitive and physical decline18,19,21. The results from this
systematic review provide evidence for a biological association between cognitive
decline and physical frailty. The potential in identifying a unique biomarker that is the
key to a specific molecular or cellular event is enticing but considering the complexity
and individual variability to aging we need to consider the possibility that these
interactions are non-linear. Several studies presented here have taken various
approaches to combining biomarkers using method such as allostatic load index,
physiologic dysfunction scores, principle components analysis (PCA), and serum protein
based algorithms (random forest methods) to yield a more accurate understanding in
the relationship between biomarkers and detection of disease18,19,21,22. Future research
should focus approaches that could include multiple markers of disease to build an
accurate model for the detection of cognitive frailty. Finding should be reproducible and
validated before translating into clinical practice. Integrating multiple biomarkers has
potential to help us better understand the complex physiological interactions. Such
validated models for disease detection will be invaluable in the prevention and early
detection of diseases unique to aging.
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Figure I. PRISMA flow diagram of study selection and citation analysis6
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Figure II. Systematic review publication date range
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Table I. Cognitive decline biomarkers by category and frequency
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Table II. Frailty biomarkers by category and frequency
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Table III. Cognitive frailty biomarkers by category and frequency
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Table IV. Serum and genetic correlations by phenotype
Phenotype assocated with serum
Serum biomarker
biomarker
Vitamin D (25(OH)D)
Frailty and cognitive decline
Cystatin C
Frailty and cognitive decline
Chemokine receptor 2 (CCR2)
Cognitive decline
Myostatin
Frailty
Klotho
Frailty
IL-6
Frailty and cognitive decline
TNF-alpha
Frailty and cognitive decline
IL-6R
Frailty and cognitive decline
CRP
Frailty and cognitive decline
IL-1βeta
Frailty and cognitive decline
IL-18
Frailty
IL-12p70
Cognitive decline
Brain derived neurotrophic factor (BDNF) Cognitive decline
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Genetic biomarker
VDR (Vitamin D receptor)
CST3 (cystatin)
CCL2
MSTN (myostatin)
KLOTHO
IL-6
TNF-alpha
IL-6R
AP2A2 (trait CRP), USP50 (trait CRP)
IL-1βeta
IL-18
IL-12A
BDNFval66Met

Phenotype assocated with genetic
biomarker
Sarcopenia
Cognitive decline
Cognitive decline
Sarcopenia
Cognitive function
Sarcopenia and cognitive decline
Sarcopenia, frailty, and cognitive decline
Cognitive decline
Cognitive decline
Cognitive decline
Frailty
Frailty
Cognitive decline
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MANUSCRIPT 3:

Establishing Biological Plausibility for Cognitive Frailty: A Population Predictive
Model
Abstract:
Background: This study aims to create a population predictive model to gain a more indepth understanding of the underlying biological mechanisms for cognitive frailty as
currently defined by the International Consensus Group in 2013. Methods: Data were
from the InCHIANTI study, collected at baseline from 1998-2000. This group is a
representative sample (n=1,453) of a population of white European origin from two
small towns in Tuscany, Italy. To build our model, we used biomarkers with implications
for clinical research and practice; a total of 132 putative SNPs and 155 protein
biomarkers were identified from a systematic review (manuscript 2). We used a tree
boosting model, Extreme Gradient Boosting (xgboost), a machine learning technique for
supervised learning. Results: We developed two predictive models with high accuracy,
AUCs for Model I is 0.877 (95% CI 0.825-0.903) and 0.864 (95% CI 0.804-0.899) for
Model II. Results provide biological evidence for the relationship between cognitive
decline and physical frailty supporting findings of dysregulation across multiple systems
as the potential cause of cognitive frailty. One of the top predictors for cognitive frailty
included anticholinergic burden with the presents of SLCO1B1 rs4363657 (TMT-A b = .20
,TMT-B b = .38). Conclusions: The results from this study establish a foundation for an
understanding of the underlying biological mechanisms for the relationship between
cognitive decline and physical frailty.
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Introduction
The relationship between the phenotypes physical frailty and cognitive decline has been
established in epidemiological studies. Both are associated with higher rates of
disability, falls, mortality, an increase in health service need, and high direct/indirect
costs to healthcare from long-term care and hospitalization1–6. Evidence exists to
support a longitudinal bidirectional relationship between physical function and cognitive
decline; finding that associations between physical functioning and consequent
cognitive decline are similar to associations with individuals with cognitive decline and
consequent physical functioning7. These findings support an a priori hypothesis for
shared biological mechanisms that underlie the association of physical and cognitive
decline.
Although physical and cognitive impairment have been shown to be related, both
phenotypes have long been studied separately4. To address this gap, the International
Consensus Group organized by the International Academy on Nutrition and Aging
(I.A.N.A) and the International Association of Gerontology and Geriatrics (I.A.G.G)
convened in 2013 to identify related domains of physical frailty and cognition. The new
construct called “cognitive frailty” is defined by the presence of physical frailty and
cognitive impairment in the absence of Alzheimer’s disease or other dementias4. The
International Consensus Group (I.A.N.A. /I.A.G.G.) report is an acknowledgment of the
need to focus research efforts on a clinical condition characterized by the occurrence of
physical frailty and cognitive impairment, in the absence of overt dementia diagnosis or
underlying neurological conditions4. The cognitive frailty construct is considered a
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heterogeneous clinical syndrome in older adults with evidence of: 1) physical frailty and
cognitive impairment; and 2) exclusion of a clinical diagnosis of Alzheimer’s Disease or
other dementia4.
The introduction of this new phenotype demonstrates evidence for cognitive frailty as
a subgroup of cognitive decline and physical frailty. Genetic risk factors and biological
markers may be unique to individuals who present with cognitive frailty in contrast to
those with isolated cognitive or physical decline. A model for detecting cognitive frailty
could provide practitioners with the tools needed for early detection and secondary
prevention for individuals with cognitive frailty. Currently, the instrumental assessments
for cognitive frailty are time-consuming, expensive, require extensive training, and the
clinical translation of these assessments is not clear4. Translating the cognitive frailty
construct into the clinical setting is limited by the lack of consensus on an operational
definition and considerable heterogeneity in the diagnostic criteria8. An understanding
of the biomarkers that define cognitive frailty will help distinguish between changes
related to normal aging, irreversible pathological process, and specific neurological
diseases that may be reversible9. The strength in understanding the biological
underpinnings of cognitive frailty is the ability to provide early detection and accurate
diagnosis.
The primary purpose of this research was to create a population predictive model to
gain a more in-depth understanding of the underlying biological mechanisms for
cognitive frailty as currently defined by the International Consensus Group in 2013. This
paper focuses on defining the shared mechanisms for physical frailty and cognitive
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impairment and establishing a model for determining the presence of risk factors that
may predict cognitive frailty in the clinical setting. An important innovation in this study
was the use of machine learning (ML) statistical modeling to define the differences
between the following groups: cognitive decline, physical frailty and cognitive frailty.
The study builds an algorithmic classifier for cognitive frailty with candidate factors
identified by a systematic review (results published elsewhere). Notably, the
identification of unique biomarkers may also serve to group patients by underlying
pathophysiologic processes and further refine the assignment to a clinical diagnostic
category. Such precision in the determination of genetic and biological biomarkers
related to cognitive frailty will lead to a better understanding of the interrelated
pathology between physical frailty and cognitive impairment and, ultimately, to early
detection and targeted interventions focused on the prevention of cognitive and
functional disabilities.
Methods
Study Population
Figure 1 shows a summary of our workflow, further details on phenotypes and the list of
biomarkers are available in the supplementary appendix. Clinical, protein, and genetic
biomarker samples were from participants of the InCHIANTI study, collected at baseline
from 1998-2000. This group is a representative sample (n=1,453) of the population of
white European origin from two small towns in Tuscany, Italy. The primary aim of the
InCHIANTI study to evaluate function and mobility in older community-dwelling
individuals. A detailed description of the study design, data collection, and sampling
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procedure are published elsewhere10. This secondary study was approved by the ethics
committee at Centre de recherché Clinique du CHUS, project #547.
Predictive Measures
The International Consensus Group’s (I.A.N.A. /I.A.G.G.) list of potential biomarkers is
not meant to be complete, accurate, or exhaustive4. Since an exhaustive list of
biomarkers is not present in the literature; we used a systematic review to identify
factors associated with cognitive decline, physical frailty, and cognitive frailty based on
the current operational definitions (Sargent et al., 2018). We searched the following
online databases: PubMed, Embase, Scopus, Web of Science, LILACS, Gene Indexer, and
GWAS Central. Databases were searched from the start date of the database to 22
December, 2015. An update of the searches was performed prior to the data extraction
phase on 26 May, 2016 to identify any new publications. The systematic review resulted
in 327 articles for the final synthesis, identifying 456 predictive protein and genetic
biomarkers. A total of 289 variables identified from the systematic review were
available in the InCHIANTI database. Variables were removed if there was > 12% missing
data, resulting in 132 putative SNPs and 155 protein biomarkers. To build our model, we
used protein markers with implications for clinical research and practice, and completed
genetic risk score estimates (i.e. the cumulative genetic risk burden estimated from
SNPs of interest, or GRS) before including the individual single nucleotide
polymorphisms (SNPs) in the final models. Many of the protein markers included in our
model are used clinically for detection of disease; therefore we organized the results by
using the clinical designation identified by clinical pathology laboratories. The categories
45

include inflammation/immunity, nutrient, lipid metabolism, metabolomics,
renal/electrolyte, hematology/liver, endocrine/hormones, and clinical features. Known
predictive clinical features identified repeatedly in the systematic review were age,
depression, gender, and level of education. Baseline diagnosis of dementia was included
in the models for frailty and cognitive frailty. Additionally, systematic review identified a
group of medications, specifically anticholinergic medications, as a risk for cognitive and
physical decline11,12. Anticholinergic burden was calculated using the Anticholinergic
Cognitive Burden Scale (ACB) and examined as a predictor for all phenotypes.
Outcome Measures
Neuropsychological tests include the Mini-Mental State Examination (MMSE) as a test of
general cognition and the Trail Making Test, Part A and B (TMT). Psychomotor speed is
assessed using the TMT-A, scoring based on time in seconds to completion with a score
range of 0 to 300 seconds13. The executive functioning domain was assessed using the
TMT-B (any individual scoring 300-600 seconds were included as 300)13. TMT, part A and
B cut off scores are based off of established norms for mild neurocognitive disorders14.
Normative data for time to complete the TMT tests in seconds was stratified by age and
education15. Additionally, the neuropsychological profile for individuals with cognitive
frailty is different from those with frailty or cognitive decline alone with recent findings
of lower performance on TMT tests, scoring worse on executive and attention
domains16. The CES-D self-report scale (0-60) is used to measure depressive symptoms.
Reliability, validity, and factor structure have been similar across a diverse demographic
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and the scale has been used extensively in epidemiologic studies for depression and
physical function17.
Frailty measures included the number of frailty symptoms for subjects ³65 years of
age. Frailty as defined by the cardiovascular health study (CHS), allows for a continuous
scoring system versus a nominal system because it can capture the multidimensional
nature of frailty18. The InCHIANTI criteria for frailty defined unintentional weight loss as
losing weight not related to diet, classified the values of body mass index, strength,
walking speed and height based on all subjects ³65 years and used two questions of the
CES-D for the definition of exhaustion.
In this study two models of cognitive frailty were developed, because conceptually
the models need to cover variables of physical frailty and cognitive decline for
populations seen in geriatric and primary care centers with implications for future
clinical research and translation into practice. Primary care has a key role in early
identification of cognitive and physical decline. The MMSE, despite known limitations
for the diagnosis of dementia, has retained popularity in the primary care setting with
increased use for screening and diagnosis and is recommended by the Alzheimer’s
Society19. Model I defines cognitive decline and cognitive frailty with the use of criteria
from the MMSE while Model II defines these phenotypes with participants who have
completed the MMSE with additional Trail Making Tests, Part A and B20–22. In this study
frailty was characterized by individuals with one or more of the frailty criteria, including
pre-frail and frail as one group1. Cognitive frailty is defined as individuals with cognitive
decline and one or more of the frailty criteria16.
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Statistical Analysis
The supplementary appendix includes additional details of the statistical methods,
beginning with detail about model development in the InCHIANTI dataset, which we
used to train and test the initial model, internal validation, and calibration of the model.
Evidence supports the use of tree boosting models using Extreme Gradient Boosting
(xgboost) in R, statistical software, as an effective method for building a reproducible
predictive model for the detection of a complex heterogeneous phenotype with large
numbers of potential biomarkers23,24. Boosted trees, a machine learning technique for
supervised learning, are ensembles of regression trees, similar to decision trees and are
used for prediction or classification. Xgboost is based in boosted trees and provides
more efficient and accurate predictive modeling with large datasets and a rapid / robust
framework for feature selection. Statistical modeling is used to design, test, and validate
an accurate method for classifying patients into phenotypic outcomes.
The tree boosting model for the evaluation of multiple variables simultaneously
provides a high predictive value with low bias. Additionally, parameters are set to
prevent over fitting for the models. The data were randomly divided, two thirds was
assigned to the training cohort, and one third was assigned to the validation cohort. One
of the features that is central to xgboost is its ability to combine multiple trees or “weak
predictors” to reach maximum prediction performance while reducing bias. This
approach uses large amounts of data from different aspects of clinical, genetic, and
biomarker research, strengthening the models’ generalizability and classification power.
Xgboost iteratively re-weighs the variables, taking a weighted majority; the parameters
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identified after pruning comprised the final predictive model25. None of the candidate
features in the models are used in the diagnosis of cognitive decline, physical frailty, or
cognitive frailty. This standard technique prevents circularity, overestimation, and over
fitting for both the models generated. Parameters for the model include: max depth =
“10”, nthread = “12”, nrounds = 5-200, objective = “binary:logistic”, evaluation metric =
“auc”, silent =”1”, gamma = default =“0” to control the number of trees, and eta
default= “0.3” to prevent over fitting. We used the default setting for all other
parameters which can be found in the xgboost 0.6 documentation24.
To evaluate the models, we used the evaluation metric area under the receiver
operating curve (AUC). AUC were calculated from each model and used to determine
discrimination of participants with cognitive frailty (case), cognitive decline (case), and
physical frailty (case) from healthy individuals (control) in the training cohort. An AUC of
0.5 was considered chance, > 0.8 informative, and > 0.9 clinically relevant.
The xgboost algorithm iteratively determines the maximum function of a model based
on a tree building algorithm (quadratic problem) which creates a node then assigns a
prediction point to each leaf; the assigned number is termed “gain”. Once the model has
reached maximum depth, pruning occurs by taking out the nodes with a negative gain
and keeping those with a positive gain. Results from the population predictive model
are ranked by gain which is a metric based on each feature’s contribution in the model.
When comparing top features to other features in the model, the higher the gain the
more important the feature is for prediction of the outcome. Cover is a measure of the
relative quantity of observations found by one feature and frequency is the percentage
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representing the relative number of time a feature is used in the trees of the model24.
Gain is the most relevant metric to interpreting the rank and importance of each
feature.
A case-control design is used to study genome wide variations between participants
with cognitive frailty (case) and those with only cognitive decline (control), only physical
frailty (control), and healthy individuals (control). Univariate analysis, t-tests for
continuous and chi-squared tests for binomial traits, were used to determine the
significance of the predictor. We used logistic regression for case-control analyses under
additive allele dosage. To evaluate additive effects of SNPs, a positive regression
coefficient means that each copy of the allele of interest increases the risk for the
cognitive frailty phenotype26,27. The appendix includes further details and results about
the generation of the genetic data and creation of the GRS from 132 genetic risk factors
implicated in one or more studies from the systematic review. Our study used the highperformance computational capabilities of the Biowulf Linux cluster at the National
Institutes of Health (Bethesda, MD, USA) in the and genotypic data from the InCHIANTI
study.
The final models identified features that were predictive of cognitive frailty with
unique features for cognitive decline and physical frailty. Mechanisms that contribute to
the development of cognitive frailty were determined by evaluation of fluid biomarkers
and genome wide genetic variability as a predictor of the development and persistence
of cognitive frailty.
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Figure 1. Study approach workflow diagram
Systematic Review and Data Cleaning: Identify the
biomarkers by phenotype, organize, and reference with
associated with InCHIANTI dataset.
Train the predictive classification models: Split data into
train and test datasets and tune xgboost to maximize test
setting based on AUC
Evaluation and calibration of the model: take selected
features from xgboost and run calibration and
comparison across groups to identify unique features.
Final predictive models for three phenotypes: Model 1
and Model 2

Note: Profile of model development and validation workflow. Blue boxes indicate steps
of the workflow specific to the InCHIANTI data set.
Results
A total of 1,453 adults participated, 1,326 provided blood samples at baseline.
Participants had a mean age of 69 years (S.D.=15.7), 56% were female and 44% were
male, and completed a secondary level of education. All participants completed the
MMSE, 369 participants scored £ 23 (M=25, S.D.=5.1), 525 scored ³ 78 on the TMT-A
(n=1,240), and 634 scored ³ 106 on the TMT-B (n=1,057).
The supplementary appendix (tables IV-IX) contains the tables for final predictive
model features ranked by gain. The results show predictive features for cognitive frailty
when measured using the MMSE (Model 1) and TMT part A and B (Model II) with unique
features for cognitive decline and physical frailty in both models. Bivariate results for
clinical, genomic, and protein biomarkers are shown in the appendix (tables X - XVIII).
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For discrimination of participants with cognitive frailty from healthy controls, the AUC
of Model I is 0.877 (95% CI 0.825-0.903) and 0.864 (95% CI 0.804-0.899) for Model II.
Parameter estimates for each predictive factor and associated descriptive statistics were
evaluated to provide biological insight into the underpinnings of the classification
algorithm. Next, we carried out calibration tests for all possible values between 5-200
groups and evaluated the distribution of the test statistics per subgrouping. We noted a
normal distribution of AUCs across all iterations, with no statistically significant
deviation from the expected values in any group, suggesting good model fit. Both
models showed high accuracy with AUCs ranging from 0.808-0.877 for model I and
0.831-0.864 model II within the framework of the calibration tests.
Demographic features and anticholinergic burden results are shown in Table 5-6 and
significant differences between healthy control and phenotype are shown in Table 10 of
the supplementary appendix. Gender was a predictor for all three phenotypes in Model
I but not a predictor in Model II. There were more females than males with cognitive
decline for all three phenotypes in both models. Baseline diagnosis of dementia, while
found to be a predictor in Model I for frailty and cognitive frailty was not a predictor in
Model II. Anticholinergic burden (ACB) was a predictor for all three phenotypes in both
models with larger ACB mean scores for those with cognitive decline, frailty, and
cognitive frailty. In Model II, anticholinergic burden had a significant effect on both
psychomotor speed (TMT-A) and executive functioning (TMT-B) for all three
phenotypes. Anticholinergic burden was found to be one of the top predictors for all
phenotypes in model I and II. Detailed analyses for anticholinergic burden are described
52

elsewhere and included in the results tables of this manuscript (Sargent et al., 2018 in
manuscript 4).
Genomic results
Table 1 and 2 shows the comparison of genomic features by phenotype for Model I and
Model II respectively.
Model I
Ten genes were predictive of cognitive frailty measured by the MMSE and CHS criteria;
four genes are unique to cognitive frailty: (BIN1) rs7561528 allele A (b = -.04), ACE
rs4968782 allele G (b = .10), and WTAPP1 rs603050 allele G (b = -.14), MTRR rs1801394
allele G (b = .80) and six overlap with features associated with cognitive decline and
frailty: IL6 rs1800796 allele C (b = .25), (ACOT11) rs12752888 allele C (b = -.47), DAB1
rs1539053 allele A (b = .51), (MMP3) rs948399 allele C (b = .41), CD33 rs3865444 allele A
(b = .62), and UBR5 rs7840202 allele C (b = -.15). Of these markers five showed a
significant difference between control and cognitive frailty: (ACOT11) rs12752888 (p =
.001), DAB1 rs1539053 (p = .01), (MMP3) rs948399 (p = .01), CD33 rs3865444 (p = .03),
and MTRR rs1801394 (p = .001).
Four SNPs were uniquely associated with frailty: CNTN5 rs10501927 allele G (b = -.10),
WTAPP1 rs11225434 allele C (b = .10), SORL1 rs4935774 allele C (b = .04), and CREBBP
rs129968 allele A (b = .10) Eight SNPs are unique to cognitive decline BTRC rs10883631
allele G (b = .11), TOMM40 rs2075650 allele G (b = .10), IL6R rs2228145 allele C (b = .31), USP50 rs3131609 allele C (b = .10), COMT rs4646316 allele T (b = -.62), AP2A2
rs7396366 allele C (b = .10), KLOTHO rs9527025 allele C (b = .20).
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Model II
Individual variants were predictive for psychomotor speed (TMT-A) and executive
functioning domain (TMT-B). Significant differences between control and disease are
shown in appendix (tables XVI - XVIII).
Twenty-one genes were predictive of cognitive frailty measured by TMT and CHS
criteria in model II; eight are unique to cognitive frailty ACE rs4316 allele T (TMT-A b = .07, TMT-B b = -.06), ACE rs1800764 allele C (TMT-A b = .06, TMT-B b = .06), EPHA1
rs11771145 allele A (TMT-A b = -.10, TMT-B b = .13), CREBBP rs129968 allele A (TMT-A b
= .05, TMT-B b = .03), TNF rs1800629 allele A (TMT-A b = .15, TMT-B b = .10), IL18
rs360722 allele A (TMT-A b = .05, TMT-B b = -.02), WTAPP1 rs603050 allele T (TMT-A b =
-.21, TMT-B b = -.10), and SELP rs6131 allele T (TMT-A b = -.07, TMT-B b = -.03).
Thirteen of the cognitive frailty genetic features overlap with variants from cognitive
decline and frailty: (MMP3) rs948399 allele C (TMT-A b = .29, TMT-B b = 0.02), (ACOT11)
rs12752888 allele C (TMT-A b = -.34, TMT-B b = -.37 ), APOE rs429358 allele C (TMT-A b
= -.23,TMT-B b = -.59), SLCO1B1 rs4363657 allele C (TMT-A b = .20 ,TMT-B b = .38),
TOMM40 rs8106922 allele G (TMT-A b = -.31, TMT-B b = .09), CNTN5 rs10501927 allele
G (TMT-A b = -.11, TMT-B b = -.06), SORL1 rs1614735 allele G (TMT-A b = .02, TMT-B b =
.07), IL1-beta rs16944 allele A (TMT-A b = -.01, TMT-B b = -.13), ACE rs4343 allele A
(TMT-A b = -.02, TMT-B b = -.02), (SSB) rs11894266 allele C (TMT-A b = -.05, TMT-B b = .06), UBR5 rs7840202 allele C (TMT-A b = -.06, TMT-B b = -.05), MAPT rs3785880 allele G
(TMT-A b = -.06, TMT-B b = -.05), BTRC rs10883631 allele G (TMT-A b = -.01, TMT-B b =
.01).
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Of these markers five showed a significant difference between control and cognitive
frailty for psychomotor speed or executive functioning: (ACOT11) rs12752888 allele C
(TMT-A, p = .01, TMT-B p = .02), APOE rs429358 allele C (TMT-B, p = .01), SLCO1B1
rs4363657 allele C (TMT-B, p= .02), TOMM40 rs8106922 allele G (TMT-A, p = .05),
(MMP3) rs948399 allele C (TMT-A, p = .05).
Frailty has one unique SNP: NECTIN2 rs6859 allele A (TMT-A b = -.02, TMT-B b = 0.07). and cognitive decline has eleven unique SNPs: KCNU1 rs1157242 allele T (TMT-A b
= .13, TMT-B b = .44), SORL1 rs1133174 allele A (TMT-A b = .05, TMT-B b = .02), KLOTHO
rs1207568 allele A (TMT-A b = -.05, TMT-B b = -.18), GCKR rs1260326 allele C (TMT-A b =
.02, TMT-B b = .08), COMT rs4680 allele A (TMT-A b = -.02, TMT-B b = .06), SORL1
rs4935774 allele C (TMT-A b = .11, TMT-B b = .05), ATM rs611646 allele T (TMT-A b =
.08, TMT-B b = .04), MS4A4E rs676309 allele C (TMT-A b = -.07, TMT-B b = -.17), SLC2A9
rs737267 allele T (TMT-A b = .10, TMT-B b = -.08), TCN2 rs740234 allele G (TMT-A b = .02, TMT-B b = -.10), (BIN1) rs744373 allele G (TMT-A b = .01, TMT-B b = -15). Cognitive
decline and frailty have three shared SNPs that were not features for cognitive frailty
PRNP rs1799990 allele G (TMT-A b = .45, TMT-B b = .30), CR1 rs3818361 allele A (TMT-A
b = .20, TMT-B b = .14), and ABCA7 rs4147929 allele A (TMT-A b = .02, TMT-B b = .03).
Protein biomarker results
Tables III and IV shows a comparison of the protein markers by category and phenotype.
Significant differences between control and cognitive frailty are shown in the
supplementary appendix (Tables XI-XVIII). The results show a mean difference in the
laboratory value between healthy controls and those with cognitive decline, physical
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frailty, and cognitive frailty. In Model I and Model II, all phenotypes share features in all
categories and each phenotype has unique features. Cognitive frailty in Model I has
seven unique features transforming growth factor B1 and fatty acid 22:0 with a mean
increase in cystatin C (p <0.0001), decrease serum calcium (p= .0004), increase serum
creatinine (p= .02), increase urine nitrites (p= .02), increase soluble transferrin receptor
(p= .01) for individuals with cognitive frailty compared to healthy controls. Cognitive
frailty (Model I) shared 70 of the 91 features with frailty and 53 of the 93 protein fluid
biomarkers features with cognitive decline. Cognitive frailty in Model II had only two
unique features; urine glucose and serum IGF binding protein; IGF binding protein is
decreased in individuals with cognitive frailty for psychomotor speed (p= .0001) and
executive functioning (p= .0004). Cognitive frailty (Model 2) shared 70 of the 90 features
with frailty and 82 of the 125 protein fluid biomarkers features with cognitive decline.
Discussion
In this study, we developed two models using xgboost for the prediction of cognitive
frailty and further defined the association between cognitive decline and frailty. Both
models have a larger population of women with older age being associated with
cognitive frailty. Anticholinergic burden was highly predictive of cognitive frailty and is
found as a unique predictive feature of frailty and cognitive decline in both models.
Genomic results suggest that Model I and Model II are measuring different variants.
Model I has unique genomic features DAB1 rs1539053 allele A, CD33 rs3865444 allele A,
and MTRR rs1801394 allele G, as predictive of cognitive frailty. CD33 has putative
functions in the immune system involved in processes at the cell membrane with links
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to greater cell surface expression of monocytes and is considered an Alzheimer’s disease
susceptibility loci28. DAB1 is required for the organization of multiple neuronal types in
the cerebral cortex and is important for normal cognitive function29,30. MTRR rs1801394
is a marker for vitamin B12 in a pathway with methylmalonic acid (MMA) levels31.
Lower serum MMA leads to higher serum lipids and higher homocysteine levels
potentially leading to reduced energy metabolism31. All three of these protein markers
were found in the cognitive frailty model I. Additionally, MTRR has been linked to 2-4
times greater odd of being frail.
One of the interesting genomic findings was SLCO1B1 rs4363657 allele C that is
predictive of frailly and cognitive frailty in Model II. The SLCO1B1 has been associated
with X12063 which is a metabolite, both are associated as markers of lean muscle mass
loss32. Additionally, SLOCO1B1 has been linked to drug metabolism specifically, higher
blood concentrations of statins33. SLOCO1B1 is essential for the hepatic uptake and the
C variant is associated with reduced OATP1B1 activity. OATP1B1 can facilitate drug
uptake and at the blood-brain barrier may affect the distribution of drugs into the
central nervous system34. The association with anticholinergic metabolism and
SLOCO1B1 has not been explored. Variants in model I and II included MMP3 and
(ACOT11). MMP3 rs948399 allele C is predictive of frailty and cognitive decline and
(ACOT11), rs12752888 allele C is a member of the acyl-CoA thioesterase family that
catalyzes the conversion of activated fatty acids35. In this study (ACOT11) rs12752888
allele C was found to have a protective effect. (ACOT11) rs12752888 has not been
studied in individuals with physical frailty or cognitive frailty previously.
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Protein marker results show a relationship between neuroinflammatory cytokines and
cognitive frailty. Neuroinflammatory cytokines (nonantibody proteins) have a role in the
neuroimmunoendocrine processes and have been postulated to be related to cognition
due to their ability to penetrate the blood-brain barrier and affect the central nervous
system1. This study found elevated levels of neuroinflammatory cytokines with
interleukins IL1, IL6, IL6R, and tumor necrosis factors (TNF) as predictive features for
cognitive frailty in both models along with associated genetic markers: IL6 rs1800796,
IL6R rs2228145, TNF rs1800629, and IL1-beta rs16944. Additionally, participants with
cognitive frailty had higher levels of resistin (p < .0001) compared to controls in both
models; resistin regulates IL-6, TNF, and hs-CRP2. Both fibrinogen and advanced
glycation end product (AGE) (p < .0001) were both found to be elevated showing a link
to oxidative stress and high levels of alpha-2 globulin (A2M) (p < .0001). A2M is
considered a protease inhibitor cytokine transporter linked to Alzheimer’s disease was
found in participants with cognitive frailty3. Several studies have shown a relationship
between many of these neuroinflammatory markers and cognitive and physical
decline5,6. In this study, we found many of these markers to be predictive for both
cognitive decline and physical frailty. Additionally, these patterns of neuroinflammatory
cytokines have been found in the InCHIANTI study to be associated with other complex
chronic disease highlighting comorbidity as a cofounding factor4.
Dehydroephiandrosterone sulfate (DHEA) was found to be low for those with
cognitive frailty when compared to control (p<0.001). DHEA has been found to inhibit IL6 providing a connection between endocrine and immune function. Another interesting
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finding is the connection between nutrition and cognitive frailty with low fatty acid
levels and high levels of c- terminal telopeptide of type-1 collagen l (PINP) and
parathyroid hormone (PTH). Both PINP and PTH have been linked to low levels of
vitamin D which was a finding in this study for participants with cognitive frailty7.
Methlymalonic acid (MMA) is linked to vitamin B12 and high levels of homocysteine
found in both models (p<.0001) in addition, MTRR rs1801394 is associated with the
same pathway. Serum MMA has been link to both cognitive performance and increased
risk for frailty8,9.
Metabolomic (ceramides C16:0, C20:0, C20:5, C22:0, C24:0) markers were found in
both models, some markers were found to be elevated and others low for participants
with cognitive frailty. Since this study evaluated individuals with early cognitive decline
at a single time point it is possible that serum ceramides varied according to the timing
and onset of memory impairment and need to be explored further10,11.
Cognitive frailty model I (n=101) and II n=110) feature comparison show a difference
some biomarkers however, there were 66 shared biomarkers; 58 protein, 4 genomic,
and 4 clinical markers. Some differences in the model features suggest lack of
concordance between the clinical measures MMSE and TMT part A and B. These
observations highlight the fact that pathways between clinical decision tools and
precision science are not strictly linear in nature. When comparing models I and II for all
phenotypes less variability with fewer unique features and more shared mechanisms.
There are several potential genomic and protein biomarker interactions, which are
not fully explored in this manuscript. We did not attempt to complete a comprehensive
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pathway analysis for the variables in the predictive models. The exploratory nature of
this work will encourage new research into understanding these pathways. The study
included a small homogenous sample with large numbers of biomarkers creating
limitations for translation into clinical research. Additionally, the study was
retrospective using existing data. Future research should be directed towards
understanding the potentially reversible cause of cognitive frailty, validating the models
in epidemiological data with more diverse demographic groups, and exploring the
predictive features in prospective studies.
Conclusion
The results from this study support the use of an innovative Boosted trees machine
learning technique in developing a population based predictive model for a complex
condition of aging, cognitive frailty. Results provide biological evidence for the
relationship between cognitive decline and physical frailty supporting findings of
dysregulation across multiple systems as the potential cause of cognitive frailty. The
results from this study begin to unravel the complex biological network behind the
association between cognitive decline and physical frailty.
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Table I. Genomic features by phenotype model I

Note: bold text indicates the closes gene

Table II. Genomic features by phenotype model II

Note: bold text indicates the closes gene
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Table III. Protein and clinical features by phenotype model I
Clinical Features
Age
Anticolnergic Burden
Depression
Gender
Level of Education
Baseline Diagnosis of Dementia
Inflammatory/Immunity
24-hour urinary cortisol (Âµg/24 hours)
Urinary cortisol (Âµg/mL)
Adiponectin via RIA (Âµg/mL)
Alpha-1 globulin (%)
Alpha-2 globulin (%)
Alpha-2-macroglobulin (mg/dL)
Cortisol:DHEAS ratio (based on nmols)
Dehydroepiandrosterone sulfate (Âµg/dL)
Fibrinogen (mg/dL)
Homocysteine via FPIA analysis (Âµmol/L)
Interleukin-10 via ELISA (pg/mL)
Interleukin-12 via Bio-Plex (pg/mL)
Interleukin-18 via ELISA ultrasensitive using plasma (pg/mL)
Interleukin-6 via ELISA ultrasensitive (pg/mL)
Resistin via EIA (ng/mL)
Serum cortisol (Âµg/dL)
Soluble IL-6 receptor via ELISA (ng/mL)
Soluble TNF-a receptor I via quantitative sandwich EIA (pg/mL)
TNF-related apoptosis-inducing ligand (pg/mL)
Uric acid (mg/dL)
Advanced glycation endproduct (AGE): Carboxymethyl-lysine (ng/mL)
Beta globulins (%)
C-reactive protein - high sensitivity (Âµg/mL)
Endogenous secretory receptor for AGEs (ng/mL)
Erythrocyte sedimentation rate (ESR) (mm/hour)
Interleukin-1 receptor antagonist via ELISA ultrasensitive (pg/mL)
Interleukin-1B via ELISA (pg/mL)
Interleukin-8 via Bio-Plex (pg/mL)
Macrophage inflammatory protein-1b via Bio-Plex (pg/mL)
Monocyte chemoattractant protein-1 via Bio-Plex (pg/mL)
Soluble CD14 via ELISA (ng/mL)
Soluble TNF-a receptor II via quantitative sandwich EIA (pg/mL)
Tumor necrosis factor-a via multiplex technology (pg/mL)
Cystatin C (mg/L)
Transforming growth factor-B1 (pg/mL)
Renal/Electrolyte
24-hour urinary creatinine (mg/24 hours)
Blood urea nitrogen (mg/dL)
Creatine phosphokinase (U/L)
Creatinine clearance, 24-hr urine (mL/minute)
Cystatin C (mg/L)
Urinary Ca (mmol/L)
Urinary Na (mmol/L)
24-hour urinary cortisol (Âµg/24 hours)
Na+ (mEq/L)
Urinary creatinine (mg/dL)
Urine proteins (mg/dL)
Ca++ (mg/dL)
Serum creatinine (mg/dL)
Urine nitrites
Nutrient Biomarker
Albumin (%)
Beta-carotene via high performance liquid chromatography (Âµmol/L)
Lycopene via high performance liquid chromatography (Âµmol/L)
Omega-3 plasma fatty acid weight (mg/L)
Omega-6 plasma fatty acid weight (mg/L)
Omega-6 fatty acids as % of total fatty acid area
Ratio of Omega-6:Omega-3 as % of total fatty acid area
Ratio of Omega-6:Omega-3 as % of total fatty acid mols
Total proteins (g/dL)
Vitamin E alpha tocopherol, high performance liquid chromatography, (Âµmol/L)
Vitamin B6 via high performance liquid chromatography (ng/mL)
Vitamin E gamma tocopherol, high performance liquid chromatography, (Âµmol/L)
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Vitamin E gamma tocopherol, high performance liquid chromatography, (Âµmol/L)
Hematology/Liver
Ferritin (ng/mL)
Folate via RIA (ng/mL)
Gamma glutamyl transferase (U/L)
GPT (also known as ALT) (U/L)
Lymphocytes (n, K/ÂµL)
MCH concentration (MCHC) (g/dL)
Mean corpuscular hemoglobin (MCH) (pg)
Mean corpuscular volume (MCV)
Methylmalonic acid MMA (Âµmol/L)"
Monocytes (%)
Red blood cells (RBC) (n, millions/ÂµL)
Red cell distribution width (RDW) (%)
Vitamin B12 via RIA (pg/mL)
White blood cells (WBC) (n, K/ÂµL)
Hematocrit (%)
Hemoglobin (g/dL)
Lymphocytes (%)
Mean corpuscular volume (MCV) (fL)
Mean platelet volume (MPV) (fL)
Methylmalonic acid, MMA (Âµmol/L)
Monocytes (n, K/ÂµL)
Neutrophils (%)
Neutrophils (n, K/ÂµL)
Retinol via high performance liquid chromatography (Âµmol/L)
Soluble transferrin receptor (nmol/L)
Lipid Metabolism
Lipids: HDL cholesterol (mg/dL)
Lipids: total cholesterol (mg/dL)
Lipids: triglycerides (mg/dL)
Lipoprotein(a) (mg/dL)
Lipids: LDL cholesterol (mg/dL)
Metabolomics(plasma lipids)
Fatty acid C16:0 (palmitic) area
Fatty acid C16:0 as % of total fatty acid area
Fatty acid C16:0 as % of total fatty acid weight
Fatty acid C16:0 (Âµmol/L)
Fatty acid C20:0 (arachidic) area
Fatty acid C20:0 as % of total fatty acid weight
Fatty acid C20:0 weight (mg/L)
Fatty acid C20:0 as % of total fatty acid area
Fatty acid C20:5 n-3 as % of total fatty acid weight
Fatty acid C20:5 n-3 weight (mg/L)
Fatty acid C20:5 n-3 as % of total fatty acid area
Fatty acid C22:0 (behenic) area
Fatty acid C22:0 weight (mg/L)
Fatty acid C22:0 as % of total fatty acid area
Fatty acid C24:0 (lignoceric) area
Fatty acid C24:0 as % of total fatty acid weight
Fatty acid C24:0 as % of total fatty acid area
Fatty acid C24:0 weight (mg/L)
Endocrine/Hormones
Blood glucose (mg/dL)
C-terminal telopeptide of type-1 collagen (ng/mL)
Estradiol via radioimmunoassay (pg/mL)
Free thyroxine, fT4 (ng/dL)
IGF binding protein-3, serum, immunoradiometric assay (ng/mL) ***corrected***
Parathyroid hormone, two-site immunoradiometric assay (pg/mL)
Plasma insulin via RIA (mIU/L)
Thyroid stimulating hormone, TSH (mIU/L)
25(OH)-D (25-hydroxyvitamin D) via RIA (nmol/L)
Free testosterone (ng/dL), Vermeulen
Total insulin-like growth factor-1, serum, immunoradiometric assay (ng/mL)
Total testosterone (ng/mL)
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Table IV. Protein and clinical marker features by phenotype model II
Clinical Features
Age
Anticholinergic Burden
Depression
Level of Education
Inflammatory/Immunity
24-hour urinary cortisol (Âµg/24 hours)
Adiponectin via RIA (Âµg/mL)
Advanced glycation endproduct (AGE): Carboxymethyl-lysine (ng/mL)
Endogenous secretory receptor for AGEs (ng/mL)
Alpha-1 globulin (%)
Alpha-2 globulin (%)
Alpha-2-macroglobulin (mg/dL)
Beta globulins (%)
C-reactive protein - high sensitivity (Âµg/mL)
C-reactive protein - low sensitivity (Âµg/mL)
Cortisol:DHEAS ratio (based on nmols)
Dehydroepiandrosterone sulfate (Âµg/dL)
Erythrocyte sedimentation rate (ESR) (mm/hour)
Fibrinogen (mg/dL)
Homocysteine via FPIA analysis (Âµmol/L)
Interleukin-1 receptor antagonist via ELISA ultrasensitive (pg/mL)
Interleukin-10 via ELISA (pg/mL)
Interleukin-12 via Bio-Plex (pg/mL)
Interleukin-18 via ELISA ultrasensitive using plasma (pg/mL)
Interleukin-1B via ELISA (pg/mL)
Interleukin-6 via ELISA ultrasensitive (pg/mL)
Interleukin-8 via Bio-Plex (pg/mL)
Macrophage inflammatory protein-1b via Bio-Plex (pg/mL)
Monocyte chemoattractant protein-1 via Bio-Plex (pg/mL)
Resistin via EIA (ng/mL)
Retinol via high performance liquid chromatography (Âµmol/L)
Serum cortisol (Âµg/dL)
Soluble CD14 via ELISA (ng/mL)
Soluble IL-6 receptor via ELISA (ng/mL)
IL-6 high-sensitivity ELISA calculated from ELISA ultrasensitive (pg/mL)
Soluble TNF-a receptor I via quantitative sandwich EIA (pg/mL)
Soluble TNF-a receptor II via quantitative sandwich EIA (pg/mL)
TNF-related apoptosis-inducing ligand (pg/mL)
Transforming growth factor-B1 (pg/mL)
Tumor necrosis factor-a via multiplex technology (pg/mL)
Uric acid (mg/dL)
Urinary cortisol (Âµg/mL)
Renal/Electrolyte
24-hour urinary creatinine (mg/24 hours)
Blood urea nitrogen (mg/dL)
Ca++ (mg/dL)
Urinary Ca (mmol/L)
Creatine phosphokinase (U/L)
Creatinine clearance, 24-hr urine (mL/minute)
Cystatin C (mg/L)
Na+ (mEq/L)
Serum creatinine (mg/dL)
Urinary creatinine (mg/dL)
Urinary Na (mmol/L)
Urine hemoglobin (mg/dL)
Urine proteins (mg/dL)
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Urine proteins (mg/dL)
Nutrient Biomarker
Albumin (%)
Beta-carotene via high performance liquid chromatography (Âµmol/L)
Lycopene via high performance liquid chromatography (Âµmol/L)
Omega-3 fatty acids as % of total fatty acid area
Omega-3 fatty acids as % of total fatty acid weight
Omega-3 plasma fatty acid weight (mg/L)
Omega-6 fatty acids as % of total fatty acid area
Omega-6 fatty acids as % of total fatty acid mols
Omega-6 fatty acids as % of total fatty acid weight
Omega-6 plasma fatty acid weight (mg/L)
Ratio of Omega-6:Omega-3 as % of total fatty acid area
Ratio of Omega-6:Omega-3 as % of total fatty acid mols
Ratio of Omega-6:Omega-3 as % of total fatty acid weight
Total proteins (g/dL)
Vitamin B6 via high performance liquid chromatography (ng/mL)
Vitamin E alpha tocopherol, high performance liquid chromatography, (Âµmol/L)
Vitamin E gamma tocopherol, high performance liquid chromatography, (Âµmol/L)
Hematology/Liver
AST (U/L)
Ferritin (ng/mL)
Gamma glutamyl transferase (U/L)
GPT (also known as ALT) (U/L)
Hematocrit (%)
Hemoglobin (g/dL)
Lymphocytes (%)
Lymphocytes (n, K/ÂµL)
MCH concentration (MCHC) (g/dL)
Mean corpuscular hemoglobin (MCH) (pg)
Mean corpuscular volume (MCV) (fL)
Methylmalonic acid, MMA (Âµmol/L)
Monocytes (%)
Monocytes (n, K/ÂµL)
Neutrophils (%)
Neutrophils (n, K/ÂµL)
Red blood cells (RBC) (n, millions/ÂµL)
Red cell distribution width (RDW) (%)
Soluble transferrin receptor (nmol/L)
Vitamin B12 via RIA (pg/mL)
White blood cells (WBC) (n, K/ÂµL)
Folate via RIA (ng/mL)
Lipid Metabolism
Lipids: HDL cholesterol (mg/dL)
Lipids: LDL cholesterol (mg/dL)
Lipids: total cholesterol (mg/dL)
Lipoprotein(a) (mg/dL)
Metabolomics(plasma lipids)
Fatty acid C16:0 as % of total fatty acid area
Fatty acid C16:0 as % of total fatty acid weight
Fatty acid C16:0 weight (mg/L)
Fatty acid C16:0 (palmitic) area
Fatty acid C20:0 (arachidic) area
Fatty acid C20:0 as % of total fatty acid area
Fatty acid C20:0 as % of total fatty acid mols
Fatty acid C20:0 as % of total fatty acid weight
Fatty acid C20:0 weight (mg/L)
Fatty acid C20:5 n-3 as % of total fatty acid area
Fatty acid C20:5 n-3 as % of total fatty acid weight
Fatty acid C20:5 n-3 cis (eicosapentaenoic, EPA) area
Fatty acid C20:5 n-3 weight (mg/L)
Fatty acid C22:0 (behenic) area
Fatty acid C22:0 as % of total fatty acid area
Fatty acid C22:0 as % of total fatty acid weight
Fatty acid C22:0 weight (mg/L)
Fatty acid C24:0 (lignoceric) area
Fatty acid C24:0 as % of total fatty acid weight
Fatty acid C24:0 as % of total fatty acid area
Fatty acid C24:0 weight (mg/L)
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Fatty acid C24:0 weight (mg/L)
Endocrine/Hormones
25(OH)-D (25-hydroxyvitamin D) via RIA (nmol/L)
Blood glucose (mg/dL)
Urine glucose (mg/dL)
C-terminal telopeptide of type-1 collagen (ng/mL)
Estradiol via radioimmunoassay (pg/mL)
Free testosterone (ng/dL), Vermeulen
Total testosterone (ng/mL)
Free thyroxine, fT4 (ng/dL)
IGF binding protein-3, serum, immunoradiometric assay (ng/mL)
IGF binding protein-3, serum, immunoradiometric assay (ng/mL) ***corrected***
Parathyroid hormone, two-site immunoradiometric assay (pg/mL)
Plasma insulin via RIA (mIU/L)
Thyroid stimulating hormone, TSH (mIU/L)
Total insulin-like growth factor-1, serum, immunoradiometric assay (ng/mL)
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MANUSCRIPT 4:

Anticholinergic Burden is a Predictor of Cognitive Decline, Physical Frailty and
Cognitive Frailty
Abstract:
OBJECTIVES: To investigate whether anticholinergic burden scores are associated with
three phenotypes; cognitive decline, physical frailty and cognitive frailty.
DESIGN: Retrospective cohort study.
SETTING: InCHIANTI study, Chianti geographic area of Tuscany, Italy.
PARTICPANTS: Population of 1,453 adults aged 20-102 years.
MEASUREMENTS: Anticholinergic burden was calculated using the Anticholinergic
Cognitive Burden Scale (ACB); neuropsychological tests included the Mini-Mental Status
Examination and Trail Making Test A and B (TMT); frailty is defined by the
Cardiovascular Heart Study, and cognitive frailty is defined by the International
Consensus Group (I.A.N.A/ I.A.G.G). Anticholinergic burden was examined as a predictor
for all phenotypes using logistic and ordinal regression models adjusting for covariates.
RESULTS: Anticholinergic burden is associated with cognitive decline, frailty, and
cognitive frailty. The odds of having cognitive decline increased by 1.21 points (95% CI =
1.06-1.37, p< .001), the odds of being frail increased by 1.33 (95% CI = 1.18-1.50, p<
.001), and the odds of cognitive frailty increased by 1.36 (95% CI = 1.21-1.54, p< .001).
Population modeling results indicated the ACB score as one of the stronger predictors
for cognitive decline, physical frailty and cognitive frailty with areas under the receiver
operating curve of 0.88 and 0.86 respectively. Anticholinergic burden association with
cognitive decline as measured by TMT adjusted for covariates was not significant; in
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contrast the relationships of ACB with cognitive frailty measured by the TMT-A and
TMT-B were statistically significant (both p< .001).
CONCLUSION: Our data support a relationship between anticholinergic burden and
cognitive decline, further strengthen the association with physical frailty and provide
new evidence for an association with cognitive frailty.
Key words: anticholinergic; burden; frailty; cognition; cognitive frailty, xgboost models
INTRODUCTION
The burden of multiple diseases perpetuates the increased consumption of medications.
Older adults are especially susceptible to polypharmacy and medication adverse risks
due to declines in physiological reserve, reduced liver and kidney function required to
metabolize medications and increased central nervous system sensitivity to
medications1. A decline in physiologic reserve coupled with the use of anticholinergic
medicines increases the risk for impaired functional and cognitive performance2–5.
Anticholinergic medications block the neurotransmitter acetylcholine in the central and
peripheral nervous system, selectively blocking acetylcholine from binding to the
muscarinic receptors in the brain6,7. Additionally, there is growing evidence that
anticholinergic affect older adults in greater proportion due to the ability of these
medications to permeate the blood-brain barrier 2,8. Anticholinergic burden is
considered to be the cumulative effect on an individual taking one or more medications
with anticholinergic activity confounded by age-related pharmacokinetic and
pharmacodynamic changes1,5,6. Higher anticholinergic burden can occur with specific
medications known to have high anticholinergic activity or with an accumulation of
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medications with low, medium, and high anticholinergic burden 9,10. An increase in
circulating anticholinergic activity causes inhibition of acetylcholine transmission to the
central nervous system suggesting a cholinergic deficit that is hypothesized to be
involved in causing impaired cognitive and motor function11. There are substantial
differences in methods for measuring anticholinergic burden and no standard or
consensus on how to quantify burden. Systematic reviews on the current anticholinergic
burden scales have all shown an association between higher anticholinergic burden and
adverse outcomes; cohort studies have mainly focused on cognitive and physical
outcomes5,9.
Less understood is the effect anticholinergic burden has on physical frailty5. Although
there is evidence to support the relationship between physical function and higher
anticholinergic burden, the methods for measuring physical functioning have focused on
activities of daily living (ADLs) and instrumental activities of daily living (IADLs) without
controlling for confounding health factors contributing to the outcome5,9. Changes in
ADLs and IDLs can be affected by multiple psychosocial and physiological factors that
are not a direct measure of disease. A recent study found a significant association of
anticholinergic burden with gait and impaired balance measured by the timed-up and
go(TUG), functional reach(FR), and grip strength(GS) assessments12. Frailty as defined by
the Cardiovascular Heart Study (CHS) is a disease process and a non-normal process of
aging13. The CHS frailty phenotype includes decline in lean body mass, strength,
endurance, balance, walking performance, and low activity13. Additionally, there is
growing evidence for a shared relationship between cognitive decline and physical
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frailty14–16. The International Consensus Group organized by the International Academy
on Nutrition and Aging (I.A.N.A) and the International Association of Gerontology and
Geriatrics (I.A.G.G) which convened in 2013 to identify related domains of physical
frailty and cognition, termed this relationship as “cognitive frailty”15.
Studies thus far have primarily used the Mini-Mental State Examination (MMSE) to
measure cognitive decline which as a composite test does not capture distinct areas of
cognitive function such as processing speed, attention, psychomotor speed, abstraction,
flexibility, ability to execute and modify a plan of action17. The goal of this study was to
use logistic and ordinal regression models to determine the relationship between
anticholinergic burden and three phenotypes: cognitive decline defined by the MMSE
and Trail Making Tests, part A and B, physical frailty, and cognitive frailty. Additionally,
we included anticholinergic burden in a separate population based predictive model
study to determine if anticholinergic burden is predictive of cognitive decline, frailty,
and cognitive frailty. The population predictive model incorporates additional measures
of disease such as protein and genomic biomarkers thereby evaluating ACB with
confounding disease processes (Sargent et al., 2018 in preparation).
METHODS
Data
The subjects in the present study were participants in Invecchaiare in Chianti (Aging in
Chianti, “InCHIANTI Study”). InCHIANTI was a prospective population based study of
1,453 adults aged 20-102 randomly selected from two towns in Tuscany, Italy using a
multistage stratified sampling at baseline from 1998 to 200018. All aspects of the
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InCHIANTI research were approved by the ethics committees at the institutions
responsible for data collection, and this secondary study was approved by the ethics
committee at Centre de recherché Clinique du CHUS, project #547. During the initial
InCHIANTI baseline 90-minute interview, information was collected on demographic and
clinical characteristics for the three phenotypes and baseline medications taken
regularly in the prior 15 days to determine anticholinergic burden. The name of the
drug, preparation and dosage were collected from medication boxes or bottles including
over the counter vitamins, food supplements, sleeping pills, or laxatives. Initial
medication information was converted from the brand name to the active ingredient.
Measures
For the current study, a total of 2,883 baseline medications were used to analyze the
anticholinergic burden effect on 1,155 individuals ³65 years of age with cognitive
decline, physical frailty, and cognitive frailty. Currently, there are 7 expert-based
anticholinergic rating scales for which quantification of the tool is based on expert
opinion, and published data, and includes both genders with a mean age of 65 years or
older4,9. The Anticholinergic Cognitive Burden (ACB) scale is the most validated scale for
evaluating adverse health outcomes including cognitive and physical function4,10. The
anticholinergic properties of each medication were quantified using the ACB scale based
on each drug’s serum anticholinergic activity19. To determine ACB scores, each
participants’ medications were assigned points (0, 1, 2, 3) according to the published
2012 update and summed for a total anticholinergic burden score. Higher scores
indicate higher anticholinergic properties. An example of medications with ACB scores
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include: Amitriptyline = 3, Amantadine = 2, and Atenolol = 1. The ACB scale has
identified medications with anticholinergic properties that have correlated with a 0.33point decline in the MMSE score over 2 years 20. The neuropsychological tests included
the MMSE as a test of general cognition and Trail Making Test, part A and B (TMT). The
TMT testing was included to further explore distinct areas of cognitive function. TMT-A
is used to assess psychomotor speed; scoring is based on time in seconds to completion
with a score range of 0 to 300 seconds21. TMT-B is used to assess the executive
functioning domain (any individual time over the limit of 300-600 seconds was included
as 300)21. Normative data for time to complete the TMT tests in seconds is stratified by
age and education22. Additionally, the neuropsychological profile for individuals with
cognitive frailty is considered to be different from those with frailty or cognitive decline
alone with recent findings of lower performance on TMT tests22,23. The Center for
Epidemiologic Studies Depression Scale (CES-D) self-report scale was used to measure
depressive symptoms. The CES-D has been used extensively in epidemiologic studies for
depression and physical function displaying similar reliability, validity, and factor
structure across a diverse demographic24.
Frailty measures included the number of frailty symptoms with performance test
data. Frailty as defined by the cardiovascular health study (CHS), allows for a continuous
scoring system versus a nominal system because it can capture the multidimensional
nature of frailty14. The components have concurrent and predictive validity with hazard
ratios (HR) ranging from 1.82-4.46 (p < 0.05) for outcomes that include incident disease,
hospitalization, falls, disability and mortality in community-dwelling older adults13. The
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InCHIANTI criteria for frailty defined unintentional weight loss as losing weight not
related to diet, classified the values of body mass index, strength, walking speed and
height based on all subjects ³65 years and used two questions of the CES-D for the
definition of exhaustion.
Phenotypic Classification
The MMSE score and the TMT part A and B was used to define two phenotypic
classifications for cognitive decline and cognitive frailty. All participants completed the
MMSE to define cognitive decline and cognitive frailty. Absence of cognitive decline is
defined as a score of 24-30 on the education adjusted MMSE 25–27. Frailty is
characterized by individuals with one or more of the Frailty criteria13. Cognitive frailty is
defined as individuals with cognitive decline and one or more of the frailty criteria23.
•

Robust with no physical frailty and absence of cognitive decline

•

Robust with no physical frailty with cognitive decline (MMSE = £ 23)

•

Frail (³ 1 criterion) and absence of cognitive decline

•

Frail (³ 1 criterion) and cognitive decline (MMSE = £ 23)

Additional phenotypic classification included mild, moderate, or severe disease defined
by the MMSE to characterize 24-30 as normal cognition, a score of 23-18 as moderate
cognitive decline (combined mild and moderate degree of impairment), and a score £ 17
as cognitive impairment25,26. Frailty is characterized by the CHS criteria cut offs and
cognitive frailty is defined as individuals with both criteria13.
•

Robust with no physical frailty and absence of cognitive decline

•

Robust with no physical frailty with mild cognitive decline (MMSE = 18-23)

•

Robust with no physical frailty with cognitive impairment (MMSE = £ 17)

•

Pre-frail (1-2 criteria) and absence of cognitive decline

•

Frail (³ 3 criteria) and absence of cognitive decline
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•

Pre-frail (1-2 criteria) and with mild cognitive decline (MMSE = 18-23)

•

Frail (³ 3 criteria) and with mild cognitive decline (MMSE = 18-23)

•

Pre-frail (1-2 criteria) and cognitive impairment (MMSE = £ 17)

•

Frail (³ 3 criteria) and cognitive impairment (MMSE = £ 17)

Additional neuropsychological testing (TMT-A and B) was used to define cognitive
decline and as part of the definition of cognitive frailty23. TMT-A and B cut off scores for
cognitive decline are based on cut off norms established by Ashendorf et al., 2008.
•

Robust with no physical frailty and absence of cognitive decline

•

Robust with no physical frailty with Cognitive Decline (both Trail A ³ 78 and Trail
B ³ 106)

•

Frail (³ 1 criterion) and Cognitive Decline (both Trail A ³ 78 and Trail B ³ 106)

•

Frail (³ 1 criterion) and Cognitive Decline (both Trail A ³ 78 and Trail B ³ 106)

Numbers of participants were insufficient for statistical analysis to include cognitive
decline or cognitive frailty categorized into levels of mild, moderate, and severe
phenotype with the TMT.
Statistical Analyses
We used logistic and ordinal regression to investigate the relationship between
anticholinergic burden and all three outcomes. Covariates were selected to control for
potential confounding effects. Demographic covariates included gender, age, and level
of education. Disease processes considered as confounders included baseline diagnosis
of: baseline dementia (n=82), vascular dementia (n=41), depression (n=412), and
Parkinson’s disease (n=16) and were included in the models as binary covariates.
In addition to the logistic and ordinal regression, ACB score was included in separate
population based predictive model analyses with 298 additional predictors; these
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included protein, clinical, and genetic markers of disease. Modeling of the dynamic
interactions between confounding disease processes determined the strength of the
relationship and predictive value for anticholinergic burden and disease outcome.
Predictive modeling via ensemble learning using xgboost allowed for better accuracy by
building multiple models, each of which learns to improve upon the errors of a prior
model producing a final model that reflects the complex interactions between biological
processes (i.e., protein and genetic biomarkers) on cognitive decline and frailty.
Parameters for the xgboost model included a stepsize eta of = “0.3”, rounds = 5-200,
max depth = “10”, nthread = “12”, objective = “binary:logistic”, evaluation metric =
“auc”, gamma = default =“0” to control the number of trees and prevent overfitting28.
Details on the population predictive model results and statistical methods beginning
with model development in the InCHIANTI dataset used to train and test classifiers,
complete internal validation, and calibration of the model are available in a separate
publication (Sargent et al., 2018 in preparation). Bivariate analyses included nonparametric Kruskal-Wallis t-tests to assess differences between groups; medians and
maximum quantiles are reported for healthy controls and three phenotypes. Next,
Bonferroni correction was conducted to adjusted for multiple comparisons; adjusted pvalues are reported. All statistical analyses were carried out using R V. 3.2.1.. R packages
included ‘glm2’-Fitting Generalized Linear Models, ‘Ordinal’-Regression Models for
Ordinal Data, and ‘xgboost’-Extreme Gradient Boosting28–30.
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RESULTS
Medication data was complete for 1,155 participants; table 1 describes the
characteristics of the participants by phenotype and the percent of individuals with a
total daily ACB score, which ranged from 0-9. Distribution of anticholinergic burden
score by phenotype and differences between health control and phenotype are shown
in Table 2. Tables displaying results for the top predictive features from the xgboost
predictive modeling study are published elsewhere (Sargent et al., 2018 in preparation)
There was a significant association between anticholinergic burden and cognitive
decline (p = 0.02), frailty (p <.001) and cognitive frailty (p <.001). Additionally, the odds
of having cognitive decline increased by 1.21 points (95% CI = 1.06-1.37, p <.001), the
odds of being frail increased by 1.33 (95% CI = 1.18-1.50, p <.001), and odds of cognitive
frailty increased by 1.36 (95% CI = 1.21-1.54, p <.001). Model fit for all three phenotypes
using the Wald chi-square test statistic was associated with a p-value of < .001,
indicating that the overall effect rank was significant. Logistic and ordinal regression
results are presented in Table 3 and 4. Results from the population predictive model are
ranked by gain, which is a metric based on each feature’s contribution in the model.
When comparing top features to other features in the model, the greater the gain the
more important the feature is for prediction of the outcome. Anticholinergic burden
was the top 4% predictor out of 105, 14% of 101, and 70% of 93 selected features during
the classifier build, with AUCs ranging from 0.81-0.88 for the outcomes frailty, cognitive
frailty, and cognitive decline respectively measured with the MMSE (Sargent et al., 2018
in preparation).
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Similarly, there was a significant association found between ACB score and cognitive
decline when measured with the TMT-A and TMT-B without adjusting for covariates.
When including the covariates age, gender, and baseline dementia individually in the
models with only ACB score for TMT-B or age and gender for TMT-A, anticholinergic
burden was no longer significant. Additionally, this was true when covariate-by-ACB
interaction terms were included; none of the interaction terms was statistically
significant (all p > 0.2). There was a significant association found between ACB score and
cognitive frailty, as measured with TMT-A (p= 0.007) and TMT-B (p < .001). Model fit for
cognitive frailty TMT-A and TMT-B using the Wald chi-square test statistic was
associated with a p-value of < .001. Logistic regression results for cognitive decline and
cognitive frailty measured with TMT are shown in Table 3. In the population predictive
modeling results, anticholinergic burden was the top 32% of 149 and 40% of 110
predictors, with AUCs ranging from 0.86-0.83 for the outcomes cognitive decline and
cognitive frailty respectively measured with the TMT-A and B (Sargent et al., 2018 in
preparation).
DISCUSSION
Participants for all phenotypes were older with a greater proportion of females; few
completed a high school education. Participants with cognitive decline, frailty, and
cognitive frailty took more medications than individuals without these phenotypes.
There were smaller numbers of participants with an ACB score > 4 with most scores
above zero clustered between 1-4; suggesting that an ACB score of 1-4 range is
sufficient to show association.
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Logistic and ordinal regression results found in this study continue to support a
relationship between anticholinergic burden and cognitive decline, further strengthen
the association with physical frailty, and provide new evidence for an association with
cognitive frailty. The population predictive model results with xgboost, showed
anticholinergic burden to be a significant predictor for all three phenotypes (Sargent et
al., 2018 in preparation).
Although frailty and cognitive decline have been shown to be related, both diseases
have long been studied separately. The findings from this study provide the first
evidence for a relationship between anticholinergic burden and cognitive frailty,
affecting both cognitive speed and executive functioning. The study results show a
relationship between anticholinergic burden and cognitive decline when measured with
the MMSE but no relationship was observed when cognitive decline was measured with
the TMT-A and TMT-B unless cognitive frailty was present. Another study found lower
executive function composite scores on the Wechsler Memory Scale-Revised, Logical
Memory Immediate Recall, and TMT-B test in a small sample (n=402) of individuals
taking anticholinergic medications over 1 year with additional findings of increased brain
atrophy and clinical decline31. Additionally, previous studies have shown a relationship
between anticholinergic burden and transitions between frailty states and increased
mortality for individuals who were robust at baseline; with every unit increase in burden
being associated with a 73% risk of transition from robust to pre-frail. Further these
studies showed that anticholinergic burden is associated with poor mobility, functional
decline, psychomotor slowing, and falls5,12,32.
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A limitation of the study is that this was a secondary analysis of existing data. As such,
the medications are from an international database and represent a specific population
of individuals and do not consider potential differences in prescribing patterns
throughout the world. Additionally, confounding may be a factor; for which it becomes
difficult to distinguish between the effects of the medications and the disease process.
Therefore, further research with adequately powered randomized controlled trials or
prospective cohort studies with follow up periods in the clinical setting are needed to
distinguish medication effect from disease progression. These findings highlight the
need for longitudinal studies focused on understanding which domains of memory are
affected.
Future research should focus on methods for detecting high risk individuals in the
clinical setting, the relationship between Apolipoprotein E e4 and anticholinergic
medications, and whether anticholinergic medications are a modifiable risk factor for
the prevention of cognitive decline and physical frailty. Identification of reversible
causes for cognitive and physical impairment is critical for the aging population.
Clinicians need to be aware of these findings and review cumulative anticholinergic
burden in robust and vulnerable individuals and minimize the overall anticholinergic
burden before symptoms of cognitive and physical decline are detectible. Until a better
understanding of the implications that these findings have in the clinical setting, caution
must be applied since medications with anticholinergic effects are used to treat many
chronic diseases, such as congestive heart failure and hypertension. These findings
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encourage new research and may lead to effective interventions for the prevention and
treatment of cognitive and physical decline in an aging population.
CONCLUSION
Anticholinergic burden is associated with both cognitive decline and physical frailty.
Efforts to better understand the epigenetic effects, sum dose effect, and identify
individuals in clinical settings who may require anticholinergic medication
discontinuation are important next steps to prevent anticholinergic burden induced
outcomes.
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Table 1. Characteristics of participants by phenotype

Phenotype (n)
Age,
mean(SD)
Gender, %
Male (n)
Female (n)
Education, %
No Education
Elementary - Secondary
High School
Medication use
Number of drugs
0 meds
1 to 4
5 to 7
8
mean(SD)
Control
Phenotype
p-value*

Cognitive
Decline
(MMSE)

Frailty
(CHS)

Cognitive
Frailty
(MMSE)

Cognitive
Decline
(TMT-A)

Cognitive
Decline
(TMT-B)

Cognitive
Frailty
(TMT-A)

Cognitive
Frailty
(TMT-B)

(n=369)

(n=595)

(n=257)

(n=525)

(n=634)

(n=302)

(n=325)

80 (8.7)

78 (7.9)

82 (7.4)

76 (7.7)

72 (9.0)

78 (7.4)

76 (6.9)

24.0 (120)
37.6 (249)

42.8 (214)
58.2 (381)

31.9 (82)
68.1 (175)

37.1 (195)
62.9 (330)

41.9 (266)
58.0 (368)

35.1 (106)
64.9 (196)

36.0 (117)
64.0 (208)

56.9 (210)
39.6 (146)
1.4 (5)

39.3 (234)
52.4 (312)
7.1 (42)

58.8 (151)
37.7 (97)
1.9 (5)

42.3 (222)
53.1 (279)
3.2 (17)

25.4 (161)
66.2 (420)
7.6 (48)

46.4 (140)
49.3 (149)
3.3 (10)

30.8 (100)
61.5 (200)
7.4 (24)

73
228
56
12
2.18 (2.01)
2.69 (2.19)
<.001

83
305
100
23
1.75 (1.76)
2.89 (2.21)
<.001

34
169
45
9
2.15 (2.02)
3.00 (2.16)
<.001

Notes: SD = standard deviation, * two tailed t-Test with means and SD

85

107
334
70
14
1.95 (1.87)
2.44 (2.12)
<.001

141
408
73
12
1.77 (1.73)
2.23 (2.02)
<.006

35
201
53
13
1.85 (1.82)
3.01 (2.20)
<.001

51
208
56
10
1.68 (1.66)
2.79 (2.19)
<.001

Table 2. Distribution of anticholinergic burden score by phenotype and difference between health control and phenotype
% (n)
ACB
0
1
2
3
4
5
6
9
Control
Phenotype
p-value*

Cognitive
Decline
MMSE
(n=296)
47.0% (139)
23.6% (70)
14.5% (43)
10.1% (30)
2.7% (8)
1.0% (3)
.7% (2)
.3% (1)
0[6]
1[9]
<.001

Frailty
CHS
(n=512)
51.0% (261)
22.9% (117)
11.9% (61)
8.8% (45)
3% (16)
1.4% (7)
.8% (4)
.2% (1)

Cognitive
Frailty
MMSE
(223)
42.2% (94)
25.1% (56)
16.1% (36)
11.2% (25)
3.1% (7)
.9% (2)
.9% (2)
.4% (1)

0[5]
0[9]
<.001

0[6]
1[9]
<.001
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Cognitive Decline
Trail A
(n=418)
57.9% (242)
20.6% (86)
10.8% (45)
6.7% (28)
2.4% (10)
1.0% (4)
.5% (2)
.2% (1)
0[5]
0[9]
<.001

Trail B
(n=493)
62.9%(310)
20.1% (99)
7.9% (39)
5.5% (27)
2.4% (12)
1.0% (5)
.2% (1)
(0)
0[4]
0[6]
.042

Cognitive Frailty
Trail A
(n=267)
50.2% (134)
22.5% (60)
13.1% (35)
8.2% (22)
3.4% (9)
1.5% (4)
.7% (2)
.4% (1)
0[5]
0[9]
<.001

Trail B
(n=274)
55.5% (152)
21.2% (58)
9.9% (27)
7.7% (21)
3.6% (10)
1.8% (5)
.4% (1)
(0)
0[4]
0[6]
<.001

Table 3. Generalized linear regression results: association between anticholinergic
burden and phenotypes
Phenotype

(n)

Beta Coef

Std. Error

95%CI

p-value

Cognitive Decline
(MMSE)

375

0.21

0.07

0.08-0.36

.004

Frailty
(CHS)

595

0.31

0.07

0.17-45

<.001

257

0.26

0.08

0.11-0.41

<.001

545

0.20

0.14

0.14-0.11

.14

703

0.21

0.14

0.10-.47

.12

302

0.27

0.08

0.11-.43

<.001

325

0.38

0.09

0.19-0.57

<.001

Cognitive Frailty
(MMSE)
Cognitive Decline
(Trail A)
Cognitive Decline
(Trail B)
Cognitive Frailty
(Trail A)
Cognitive Frailty
(Trail B)

Table 4. Ordinal regression results: association between anticholinergic burden
and phenotype
Models
1

2

3

Phenotypes (MMSE & CHS)
Cognition
Cognitive Decline
Cognitive Impairment
Frailty
Frail
Pre-frail
Cognitive Frailty
Cognitive Decline & Frail
Cognitive Decline & Pre-frail

n
501
101
88
507
55
217

Cognitive Impaired & Frail
Cognitive Impaired & Pre-frail
Models

Phenotype

11
76

Beta Coef

Std.
Error

Odds
Ratio

95%CI

p-value

1

Cognition

0.19

0.07

1.21

1.07-1.37

<.001

2

Frailty

0.29

0.06

1.33

1.87-1.50

<.001

3

Cognitive
Frailty

0.31

0.06

1.36

1.21-1.54

<.001
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SUMMARY
This dissertation consists of four manuscripts; 1) an integrative review of the
measurements for cognitive frailty, 2) a systematic review of the clinical and biological
markers for cognitive decline and physical frailty, 3) an innovative population predictive
model analyses establishing biological plausibility for cognitive frailty, 4) and a new
finding of anticholinergic burden as a predictor of frailty and cognitive frailty. The results
from this study establish a foundation for an understanding of the underlying biological
mechanisms for the relationship between cognitive decline and physical frailty and
found anticholinergic burden as one of the top predictors for frailty and cognitive frailty.
In seeking to explore the importance and applicability of these results it is critical that
others continue to replicate the model results. To accompany manuscript 3, help with
replication and extension of this work, the code has been made publically available for
the population predictive model.
Implications
The results from this dissertation have several implications for future research and
have a potential for translation into practice. Through the lens of Complex Systems
Theory, this dissertation begins to unravel the complexity behind a geriatric syndrome
providing biological plausibility to cognitive frailty. Geriatric syndromes such as cognitive
frailty are highly multifactorial and variable across the aging spectrum lending
themselves to new ways of investigation. As Bryne (1998) notes: Not only can the
complex not always be derived, even in principle from the less complex,… we can often
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only understand the simpler [cognitive frailty] in terms of its origins in the more complex
(p. 16). By using the framework of complex systems theory and an innovative Boosted
trees machine learning technique (xgboost) we determined key biological mechanism
for a dysregulation across multiple systems as the potential cause for cognitive frailty.
The future to understanding complex geriatric syndrome should include a systems
approach by using highly accurate statistical modeling to identify measurable markers.
There were multiple biological associations determined by the study results that should
be investigated further. One of the interesting findings is anticholinergic burden in
conjunction with the association of SLCO1B1 as predictors for cognitive frailty. SLO1B1 is
an important pharmacokinetic gene that is involved in the removal of drug compounds
and transport of drug metabolites at the blood-brain barrier(1). It has been implicated
as a marker of lean muscle mass loss and may affect the distribution of drugs into the
central nervous system(1,2).
Limitations
The limitations of the dissertation research included the use of a small homogenous
sample with large numbers of biomarkers creating limitations for translation into clinical
research. Additionally, the study was retrospective using existing data. The analyses
used a randomly assigned training subset to validate the model within a relatively
homogenous InCHIANTI cohort. Additionally, no external validation of the model was
completed. The model would be strengthened by external validation in a in a mixed
ethnic and demographic age range. Through the process of completing this dissertation I
have gained invaluable expertise in statically modeling of a large dataset and have
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learned skills in the field of bioinformatics. The dissertation required me to learn bash
and R coding, along with learning how to manipulate genetic data in PLINK.
Future research
There are several areas for future research based on this dissertation work. There is a
need to test and validate the model in a second more ethnically diverse population
before translation into clinical practice. Further investigate anticholinergic burden as an
epigenetic cause of cognitive frailty by exploring the relationship between putative
genetic markers discovered in the model analyses (i.e. SLCO1B1 and COMT). Some of
these findings can be translated into clinical studies. Research focusing on methods for
detecting high-risk individuals in the clinical setting and descriptive studies to
understand the scope and effect of cognitive frailty are needed. Intervention studies are
essential to understanding the role of nutrition and/or physical activities have on
neuroinflammatory cytokines and other system markers for cognitive frail individual’s
progression. Additionally, further work can be done on whether anticholinergic
medications are a modifiable risk factor for the prevention of cognitive frailty.
Identification of reversible causes for cognitive and physical impairment is critical for the
aging population.
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APPENDICES

MANUSCRIPT 1: Supplemental documents
Appendix(A.(Search(Strategies(–(Conducted(January(30,(2015(
Database(

Added(
Filters(
English,'
Human'

Time(
Period(
19837
Present'

CINAHL'

English,'
Human'

19927
Present'

PsycInfo'

None'

20057
Present'

Dissertation'
&'Thesis'

None'

19847
Present'

Web'of'
Science'

English'

19917
Present'

PubMed'

Terms(

Results(
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MANUSCRIPT 2: Supplemental documents
Table I. Clinical and biomarkers results
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Table II. Genetic studies for cognitive decline and frailty
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Figure I. PubMed search strategy
((“Frailty”[TIAB] OR “Frail”[TIAB] OR “Physical Frailty”[TIAB] OR "Frail Elderly"[Mesh] OR “Sarcopenia”[Mesh] OR
"Muscle Weakness"[Mesh] OR “hand strength”[Mesh] OR “motor activity”[Mesh] OR “weight loss”[Mesh] OR
“fatigue”[Mesh] OR “lassitude”[tiab] OR “motor activity”[tiab] OR “motor activities”[tiab] OR “physical
activities”[tiab] OR “locomotor activity”[tiab] OR “locomotor activities”[tiab] OR “hand strength”[tiab] OR
“grip”[tiab] OR “grips”[tiab] OR “grasp”[tiab] OR “grasps”[tiab] OR “gait speed”[tiab] OR “grip strength”[tiab] OR
“physical activity”[tiab] OR “weight loss”[tiab] OR “fatigue”[tiab] OR “sarcopenia”[tiab] OR “tiredness”[tiab] OR
“muscular weakness”[tiab])
OR
(“Alzheimer Disease”[Mesh] OR “Dementia”[Mesh] OR “Mild Cognitive Impairment”[Mesh] OR “Cognition
Disorders”[Mesh] OR “Alzheimer”[tiab] OR “Alzheimers”[tiab] OR “Alzheimer’s”[tiab] OR “presenile dementia”[tiab]
OR “senile dementia”[tiab] OR “cognitive impairment”[tiab] OR “cognitive impairments”[tiab] OR “neurocognitive
disorder”[tiab] OR “neurocognitive disorders”[tiab] OR “dementia”[tiab] OR “dementias”[tiab] OR “cognitive
decline”[tiab] OR “cognitive declines”[tiab] OR “cognition disorder”[tiab] OR “cognition disorders”[tiab])
OR
(“cognitive frailty”[tiab])
AND
(("Biomarkers "[Mesh] OR "biological markers”[tiab] OR "biological marker”[tiab] OR “biologic markers”[tiab] OR
“biologic marker”[tiab] OR "biomarkers”[tiab] OR "biomarker”[tiab] OR "clinical markers”[tiab] OR "clinical
marker”[tiab] OR “Immunologic markers”[tiab] OR “immunologic marker”[tiab] OR “immune marker”[tiab] OR
“immune markers”[tiab] OR “viral markers”[tiab] OR “viral marker”[tiab] OR “serum markers”[tiab] OR “serum
marker”[tiab] OR “surrogate endpoints”[tiab] OR “surrogate endpoints”[tiab] OR “surrogate end points”[tiab] OR
“surrogate end point”[tiab] OR “surrogate markers”[tiab] OR “surrogate marker”[tiab] OR “biochemical
markers”[tiab] OR “biochemical marker”[tiab] OR “laboratory markers”[tiab] OR “laboratory marker”[tiab] OR
“disease marker”[tiab] OR “disease markers”[tiab] )
OR
(“Genetic markers”[Mesh] OR “genetic markers”[tiab] OR “genetic marker”[tiab] OR “DNA markers”[tiab] OR “DNA
marker”[tiab] OR “Chromosome marker”[tiab] OR “Chromosome markers”)
OR
("Genome-Wide Association Study"[Mesh] OR “genome wide association”[tiab] OR “whole genome
association”[tiab] OR “GWAS”[tiab] OR “candidate gene study”[tiab] OR “candidate gene studies”[tiab]))
AND
("Clinical Trials as Topic"[Mesh] OR "Clinical Trial" [Publication Type] OR "Randomized Controlled Trial" [Publication
Type] OR "Longitudinal Studies"[Mesh] OR "Random Allocation"[Mesh] OR "Cross-Sectional Studies"[Mesh] OR
“clinical trial”[tiab] OR “clinical trials”[tiab] OR “randomized controlled”[tiab] OR “randomised controlled”[tiab]
“random allocation”[tiab] OR “cross sectional study”[tiab] OR “cross sectional studies”[tiab] OR “cross sectional
analysis”[tiab] OR “cross sectional analyses”[tiab] OR “longitudinal study”[tiab] OR “longitudinal studies”[tiab] OR
“cross sectional survey”[tiab] OR “cross sectional surveys”[tiab] OR “prevalence study”[tiab] OR “prevalence
studies”[tiab] OR “randomization”[tiab] OR “randomisation”[tiab] OR “cross-sectional research”[tiab] OR “crosssectional design”[tiab] OR "Genome-Wide Association Study"[Mesh] OR “genome wide association”[tiab] OR
“whole genome association”[tiab] OR “GWAS”[tiab] OR “candidate gene study”[tiab] OR “candidate gene
studies”[tiab])
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MANUSCRIPT 3: Supplementary Methods, Statistical and Genomic Analyses
Reproducibility
In seeking to explore the importance and applicability of these results it is critical that others
continue to replicate model results before they can be used in the clinical setting. To
accompany this report, help with replication and extension of our work, the code has been
made publically available for model I and model II online.
Database
The subjects in the present study were participants in Invecchaiare in Chianti (Aging in Chianti,
“InCHIANTI Study”). InCHIANTI is a prospective population based study of 1,453 adults aged 20102 randomly selected from two towns in Tuscany, Italy using a multistage stratified sampling
at baseline from 1998 to 20001. All aspects of the InCHIANTI research were approved by the
ethics committees at the institutions responsible for data collection.
Definitions used to establish phenotype sub-groups in this study
Cognitive decline – mild neurocognitive disorders
Evidence of modest cognitive decline from a previous level of performance in one or more
cognitive domains (complex attention, executive function, learning and memory, language,
perceptual motor, or social cognition) with a modest impairment in cognitive performance by
standardized neuropsychological testing or clinical assessment in absence of a diagnosis of
dementia2,34.
Frailty
The operational definition for frailty is defined as a clinical syndrome condition including 3 out
of the 5 criteria related a physical phenotype including: 1) weak muscle strength (grip strength),
2) slow gait speed, 3) unintentional weight loss, 4) exhaustion and low physical activity5. Prefrailty includes 1 or 2 of the criteria is present, identifying a sub-group of individuals potentially
progressing to frailty5.
Cognitive Frailty
A syndrome in older adults with evidence of both physical frailty and cognitive impairment
without a clinical diagnosis of Alzheimer’s Disease or other dementia6.
Phenotypic classification for this study
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Model I
Participants with an MMSE normal cognition 24-30 and cognitive decline £ 237–9. In this study
frailty is characterized by individuals with one or more of the frailty criterion5. Cognitive frailty
is defined as individuals with cognitive decline and one or more of frailty criterion10.
•

Robust with no physical frailty and absence of cognitive decline

•

Robust with no physical frailty with cognitive (MMSE = £ 23)

•

Frail (³ 1 criteria) and absence of cognitive decline

•

Frail (³ 1 criteria) and cognitive decline (MMSE = £ 23)

Model II
Participants that completed the MMSE with additional neuropsychiatric testing Trail Making
Test, Part A and B (TMT) to define cognitive decline and cognitive frailty10,11. TMT cut off scores
for cognitive decline are based on cut off norms established by Ashendorf et al., 2008.
•

Robust with no physical frailty and absence of cognitive decline

•

Robust with no physical frailty with cognitive decline (Trail A ³ 78, Trail B ³ 106)

•

Frail (³ 1 criteria) and cognitive decline (Trail A ³ 78, Trail B ³ 106)

•

Frail (³ 1 criteria) and cognitive decline (Trail A ³ 78, Trail B ³ 106)

Laboratory assay methods
At the baseline survey, most of the participants performed 24-hour urine collection early in the
morning mid-stream sample urine for the routine examination. Total urinary polyphenols were
measured at the Department of Food Science and Technology, School of Pharmacy, University
of Barcelona, Spain. Prior to blood collection all participants consumed a diet free of meat and
fish. Participants donated fasting blood samples for routine blood examinations. Blood
collection was performed with the standard procedure method to prevent red cell hemolysis.
The blood collection included two sets of collection tubes: one for routine tests and second for
collecting specimens including serum, plasma, DNA for the biological bank. All routine blood
tests, performed in the Laboratory of Clinical Chemistry and Microbiological Assays, Annunziata
Hospital in Florence, Italy. Plasma fatty acids (FAs) were measured by the Section of
Gerontology and Geriatrics, Department of Clinical and Experimental Medicine, Perugia, Italy.
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The technique used was gas chromatography with a fused silica capillary column to achieve the
optimum separation of the different fatty acids.
Software for analyses
All statistical analyses were carried out using R V. 3.2.1. R is free, open-source software that
provides many statistical and graphic techniques. R packages used included ‘glm2’-Fitting
Generalized Linear Models, ‘Ordinal’-Regression Models for Ordinal Data, and ‘xgboost’Extreme Gradient Boosting12–14. The software package PLINK, an analysis toolset was used for
the management of genotype data and basic associating testing15,16.
Model generation
The predictive genetic and laboratory biomarkers were identified in a comprehensive
systematic review and analyzed using an Extreme Gradient Boosting (xgboost) in R14. While
boosting was initially developed for machine learning, ‘xgboost’ in R is based in boosted trees.
Xgboost is an open source tool and a variant of the gradient boosting machine and uses a tree
based model. Xgboost is used in this study for a supervised learning problem where the
variables identified from the systematic review are used to predict three phenotypes cognitive
decline, physical frailty, and cognitive frailty.
Evaluation of the model
With the use of any predictive model in machine learning there is a chance for inflated risk of
capitalizing on chance features (over fitting) in the data. Over fitting of the integrative model
was mitigated in two ways: 1) having a distinct training and validation process for the model
and 2) using xgb in R which has a built-in parameter settings for selection to reduce poor
predictive performance. Internal validation: A randomly assigned training subset was used to
validate the model within the InCHIANTI cohort in silico (via simulation).
Calibration of the model
Parameter estimates for each predictive factor and associated descriptive statistics was
evaluated to provide biological insight into the underpinnings of the classification algorithm.
We first evaluated the calibration by partitioning the data into 5, 10, 20, 30, 40, 50, 75, 100 and
200 groups and then ran the calibration test. Next, we repeated tests for all possible values
between 5-200 groups and evaluated the distribution of the test statistic. The best prediction
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thresholds were determined using AUC, 87.7% for Model I and 86.4% for Model II. Population
predictive features by phenotype ranked by gain for Model I are presented in Tables 4-6 and
Model II Tables 7-9.
Genetic Data
Genotypic data was generated at the National Institute on Aging’s Laboratory of Neurogenics.
Samples of genomic DNA extracted from leukocytes17. Genotypic data used for the model were
extracted out of the binary Plink files from the InCHIANTI database. SNPs which could not be
identified in the binary files were extracted from genotype imputed files, genotype imputation
was completed with Minimac (V2). The SNPs included meet the following standard: per variant
and per sample missingness < 5%, European ancestry, MAF < 0.001 and a rsq < 0.3. Additionally,
Samples were filtered for 95% or greater genotyping call rate, no ancestry outliers, and no sex
discrepancies.
Supplementary Data Table I: Laboratory values as they appear in the InCHIANTI Datasets by Clinical
Category
Inflammatory/Immunity
Nutrient Biomarker
Lipid Metabolism
BL Omega-3 fatty acids as % of BL Lipids: total cholesterol
BL Uric acid (mg/dL)
total fatty acid area
(mg/dL)
BL Omega-3 plasma fatty acid
BL Lipids: HDL cholesterol
BL Urinary cortisol (µg/mL)
weight (mg/L)
(mg/dL)
BL 24-hour urinary cortisol
BL Omega-3 fatty acids as % of
BL Lipids: triglycerides (mg/dL)
(µg/24 hours)
total fatty acid weight
BL C-reactive protein - low
BL Omega-3 fatty acids as % of BL Lipids: LDL cholesterol
sensitivity (µg/mL)
total fatty acid mols
(mg/dL)
BL C-reactive protein - high
BL Omega-6 fatty acids as % of
BL Lipoprotein(a) (mg/dL)
sensitivity (µg/mL)
total fatty acid area
BL Interleukin-6 via ELISA
BL Omega-6 plasma fatty acid
ultrasensitive (pg/mL)
weight (mg/L)
BL IL-6 high-sensitivity ELISA
BL Omega-6 fatty acids as % of
calculated from ELISA
Metabolomics(plasma lipids)
total fatty acid weight
ultrasensitive (pg/mL)
BL Soluble IL-6 receptor via ELISA BL Omega-6 fatty acids as % of BL Fatty acid C16:0
(ng/mL)
total fatty acid mols
(palmitiA91:A116c) area
BL Interleukin-10 via ELISA
BL Ratio of Omega-6:Omega-3
BL Fatty acid C16:0 (palmitic)
(pg/mL)
as % of total fatty acid area
area
BL Interleukin-1 receptor
BL Ratio of Omega-6:Omega-3
BL Fatty acid C16:0 as % of total
antagonist via ELISA
as % of total fatty acid weight
fatty acid area
ultrasensitive (pg/mL)
BL Interleukin-1B via ELISA
BL Ratio of Omega-6:Omega-3
BL Fatty acid C16:0 weight
(pg/mL)
as % of total fatty acid mols
(mg/L)
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BL Interleukin-18 via ELISA
ultrasensitive using plasma
(pg/mL)
BL Transforming growth factorB1 (pg/mL)
BL Tumor necrosis factor-a via
multiplex technology (pg/mL)
BL Soluble TNF-a receptor I via
quantitative sandwich EIA
(pg/mL)
BL Soluble TNF-a receptor II via
quantitative sandwich EIA
(pg/mL)
BL TNF-related apoptosisinducing ligand (pg/mL)
BL Interleukin-8 via Bio-Plex
(pg/mL)
BL Interleukin-12 via Bio-Plex
(pg/mL)
BL Monocyte chemoattractant
protein-1 via Bio-Plex (pg/mL)
BL Macrophage inflammatory
protein-1b via Bio-Plex (pg/mL)

BL Vitamin B6 via high
performance liquid
chromatography (ng/mL)
BL Vitamin B6 via high
performance liquid
chromatography (nmol/L)
BL Vitamin E gamma
tocopherol, high performance
liquid chromatography
(µmol/L)
BL Vitamin E alpha tocopherol,
high performance liquid
chromatography (µmol/L)
BL Vitamin E gamma
tocopherol, high performance
liquid chromatography, assay
#2 (µmol/L)
BL Vitamin E alpha tocopherol,
high performance liquid
chromatography, assay #2
(µmol/L)
BL Beta-carotene via high
performance liquid
chromatography (µmol/L)
BL Lycopene via high
performance liquid
chromatography (µmol/L)
BL Total proteins (g/dL)
BL Albumin (%)

BL Serum cortisol (µg/dL)
BL Serum cortisol (nmol/L)
BL Dehydroepiandrosterone
sulfate (µg/dL)
BL Dehydroepiandrosterone
sulfate (nmol/L)
BL Cortisol:DHEAS ratio (based
on nmols)
BL Soluble CD14 via ELISA
(ng/mL)

BL Fatty acid C16:0 as % of total
fatty acid weight
BL Fatty acid C16:0 (µmol/L)

BL Fatty acid C16:0 as % of total
fatty acid mols
BL Fatty acid C20:0 (arachidic)
area
BL Fatty acid C20:0 as % of total
fatty acid area

BL Fatty acid C20:0 weight
(mg/L)
BL Fatty acid C20:0 as % of total
fatty acid weight
BL Fatty acid C20:0 (µmol/L)
BL Fatty acid C20:0 as % of total
fatty acid mols
BL Fatty acid C20:5 n-3 cis
(eicosapentaenoic, EPA) area
BL Fatty acid C20:5 n-3 as % of
total fatty acid area
BL Fatty acid C20:5 n-3 weight
(mg/L)
BL Fatty acid C20:5 n-3 as % of
total fatty acid weight
BL Fatty acid C20:5 n-3 (µmol/L)
BL Fatty acid C20:5 n-3 as % of
total fatty acid mols
BL Fatty acid C22:0 (behenic)
area
BL Fatty acid C22:0 as % of total
fatty acid area
BL Fatty acid C22:0 weight
(mg/L)

BL Fibrinogen (mg/dL)
BL Erythrocyte sedimentation
rate (ESR) (mm/hour)
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BL Homocysteine via FPIA
analysis (µmol/L)
BL Resistin via EIA (ng/mL)BL Adiponectin via RIA (µg/mL)(metabolic function)
BL Advanced glycation
endproduct (AGE):
Carboxymethyl-lysine (ng/mL)

BL Fatty acid C22:0 as % of total
fatty acid weight
BL Fatty acid C22:0 (µmol/L)
BL Fatty acid C22:0 as % of total
fatty acid mols
BL Fatty acid C24:0 (lignoceric)
area
BL Fatty acid C24:0 as % of total
fatty acid area
BL Fatty acid C24:0 weight
(mg/L)
BL Fatty acid C24:0 as % of total
fatty acid weight
BL Fatty acid C24:0 (µmol/L)
BL Fatty acid C24:0 as % of total
fatty acid mols

BL Alpha-1 globulin (%)
BL Alpha-2 globulin (%)
BL Alpha-2-macroglobulin
(mg/dL)
BL Beta globulins (%)
BL Endogenous secretory
receptor for AGEs (ng/mL)

Renal/Electrolyte
BL Na+ (mEq/L)
BL Ca++ (mg/dL)

Hematology/Liver
BL White blood cells (WBC) (n,
K/µL)
BL Neutrophils (n, K/µL)

BL Urinary creatinine (mg/dL)

BL Lymphocytes (n, K/µL)

BL 24-hour urinary creatinine
(mg/24 hours)
BL Creatinine clearance, 24-hr
urine (mL/minute)
BL Urinary Ca (mmol/L)

BL Monocytes (n, K/µL)

BL Urinary Na (mmol/L)
BL Urine glucose (mg/dL)
BL Urine proteins (mg/dL)

BL Monocytes (%)
BL Red blood cells (RBC) (n,
millions/µL)
BL Hemoglobin (g/dL)

BL Urine hemoglobin (mg/dL)

BL Hematocrit (%)

BL Urine ketones (mg/dL)

BL Mean corpuscular volume
(MCV) (fL)
BL Mean corpuscular
hemoglobin (MCH) (pg)
BL MCH concentration (MCHC)
(g/dL)

BL Urine bilirubin (mg/dL)
BL Urine urobilinogen (mg/dL)

BL Neutrophils (%)
BL Lymphocytes (%)
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Endocrine/Hormones
BL Blood glucose (mg/dL)
BL 25(OH)-D (25-hydroxyvitamin
D) via RIA (nmol/L)
BL Parathyroid hormone, twosite immunoradiometric assay
(pg/mL)
BL Thyroid stimulating
hormone, TSH (mIU/L)
BL Free thyroxine, fT4 (ng/dL)
BL Plasma insulin via RIA
(mIU/L)
BL Total testosterone (ng/mL)
BL Total testosterone (nmol/L)
BL Free testosterone (ng/dL),
Vermeulen
BL Free testosterone (nmol/L),
Vermeulen
BL Estradiol via
radioimmunoassay (pg/mL)
BL Estradiol via
radioimmunoassay (nmol/L)
BL C-terminal telopeptide of
type-1 collagen (ng/mL)

BL Urine nitrites

BL Red cell distribution width
(RDW) (%)

BL Serum creatinine (mg/dL)

BL Mean platelet volume
(MPV) (fL)

BL Blood urea nitrogen (mg/dL)

BL Ferritin (ng/mL)

BL Creatine phosphokinase (U/L)
BL Cystatin C (mg/L)

BL Folate via RIA (ng/mL)
BL Folate via RIA (nmol/L)
BL Vitamin B12 via RIA (pg/mL)
BL Vitamin B12 via RIA
(pmol/L)
BL Methylmalonic
acid(methylmalonic aciduria),
MMA (µmol/L)
BL Soluble transferrin receptor
(nmol/L)
BL Soluble transferrin receptor
(mg/L)
BL GOT (also known as AST)
(U/L)
BL GPT (also known as ALT)
(U/L)
BL Gamma glutamyl
transferase (U/L)
BL Retinol via high
performance liquid
chromatography (µmol/L)
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BL Total insulin-like growth
factor-1, serum,
immunoradiometric assay
(ng/mL)-(IGFBP1)
BL IGF binding protein-3, serum,
immunoradiometric assay
(ng/mL) ***corrected***
BL IGF binding protein-3, serum,
immunoradiometric assay
(nmol/L)

Supplementary Data Table II: Variants included in the Genomic Risk Score GRS calculations and
individual effect estimates of single variants for predictive modeling. Phenotype association is based
on the findings from the systematic review and the relationship found between variant and disease
outcome.
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Notes: *Proxy SNP, Cog/Frail – variant was found for both phenotypes in the systematic review, bold
text indicates the closest gene
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Genetic risk scores
One hundred and thirty-one variants where catalogued from a large systematic review and
used to construct genetic risk scores for three models. All variants were used to create an all
risk score (n=132), variants related to the phenotypes cognitive decline and physical frailty
constructed cognitive risk scores (n=105) and frailty risk scores (n=27). Risk scores were
calculated by summation of the number of risk alleles across all the variants divided by the
number of SNPs in the score to obtain an average number of risk alleles per locus. After the
scaled risk allele counts were summed and divided by the number of loci, they were
transformed into Z scores. Z score transformation assists in communicating the effect estimates
with the Z corresponding to a single standard deviation from the control mean genetic risk for
the phenotypes. All risk scores were calculated using PLINK. R V. 3.2.1 was used to fit
multinomial and logistic regression models using standard covariates and risk scores as
predictors of cognitive decline, physical frailty, and cognitive frailty as the outcome variable.
Stepwise backward and forward selection using AIC and p values facilitated the best fit models.
Supplementary Table III:
Model I Genetic risk scores – Population predictive model features by phenotype
Phenotype (n)
All Risk Scores
Cognition Risk Scores
Cognitive Decline
p
MMSE (369)
.1286
.0659
.12
.15
b
.08
.08
SE
Frail
CHS (595)

p
b
SE

Cognitive frailty
MMSE (257)

p
b
SE

Frail Risk Scores
.8768
-.01
.08

.0488
0.14
0.07

.0401
.14
.07

.6509
.03
.07

.0455
0.19
0.10

.0479
.19
.10

.7775
-0.03
.09
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Model II Genetic risk scores – Population predictive model features by phenotype
Phenotype (n)
All Risk Scores
Cognition Risk Scores Frail Risk Scores
Cognitive Decline
p
.6097
.5959
.4440
Trail B (634)
.05
.05
-.07
b
SE
.09
.09
.09
Cognitive Decline
p
.0351
.0370
.3274
Trail A (525)
.16
.16
.07
b
SE
.08
.07
.07
Cognitive Frailty
p
.2082
.1992
.7394
Trail B (325)
.11
.11
.03
b
SE
.08
.09
.08
Cognitive Frailty
p
.6298
.4242
.2734
Trail A (302)
.04
.06
-.08
b
SE
.08
.08
.08
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Table IV: Cognitive Decline Features Model I
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Table V: Frailty Features Model I
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Table VI: Cognitive Frailty Features Model I
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Table VII: Cognitive Decline Features Model II
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Table VIII: Frailty Features Model II
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Table IX: Cognitive Frailty Features Model II
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Table X. Clinical features by healthy control and phenotype
Model 1

Cognitive Decline
mean(SD)

Frailty
p-value

mean(SD)

Cognitive Frailty
p-value

mean(SD)

p-value

Age
Control
Phenotype
Anicholinergic Burden
Control
Phenotype
Gender
Healthy Control(M/F)
Phenotype(M/F)
Depression
Control
Phenotype
Baseline Dementia
Control
Phenotype
Model 2
Age
Control
Phenotype
Anicholinergic Burden
Control
Phenotype
Depression
Control
Phenotype

65(15.7)
80(8.7)
2.18 (2.01)
2.69 (2.19)
(n)
521/557
121/254
272
140

Cognitive Decline
TrailA
mean(SD)
61(16.4)
76(7.7)
1.95 (1.87)
2.44 (2.12)
(n)
135
339

<0.0001

72(6.2)
78(7.9)

<0.0001

1.75 (1.76)
2.89 (2.21)
(n)
286/274
214/381

<0.0001

<0.0001

<0.0001

73(6.4)
82(7.4)

<0.0001

<0.0001

2.15 (2.02)
3.00 (2.16)
(n)
418/480
82/175

91
269

<0.0001

250
110

<0.0001

12
70

<0.0001

12
70

<0.0001

<0.0001

<0.0001

<0.0001

Frailty
p-value
<0.0001

<0.0011

<0.0001

TrailB
mean(SD)
52(17.4)
72(9.0)
1.77 (1.73)
2.23 (2.02)
(n)
52
220

p-value
<0.0001

0.042

<0.0001

mean(SD)
72(6.2)
78(7.9)
1.75 (1.76)
2.89 (2.21)
(n)
91
269
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p-value
<0.0001

<0.0001

<0.0001

Cognitive Frailty
TrailA
mean(SD)
64(15.6)
78(7.4)
1.85 (1.82)
3.01 (2.20)
(n)
188
151

TrailB
mean(SD)
61(16.2)
<0.0001
76(6.9)

p-value

1.68 (1.66)
2.79 (2.19)
(n)
120
<0.0001
152

<0.0001

p-value
<0.0001

<0.0001

<0.0001

Table XI. Genomic univariate results Model I

Note: bold text indicates the closes gene

Table XII. Genomic univariate results Model II

Note: bold text indicates the closes gene
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Table XIII. Difference between health control and cognitive decline results Model I

Corrected
og.Model1.Feature.code Cognitive Decline Model1
Control Mean SD
Cognitive Mean SD
|t|-test
p-value
_25OH_D
25(OH)-D (25-hydroxyvitamin D) via RIA (nmol/L)
56.26 36.69
39.66 29.96 <0.0001 <0.0001
_ADIPON
Adiponectin via RIA (µg/mL)
12.50
8.79
17.15 12.21 <0.0001 <0.0001
_ALB
Albumin (%)
59.58
3.40
57.43
3.86 <0.0001 <0.0001
_ALF2M
Alpha-2-macroglobulin (mg/dL)
203.26 66.61
222.27 66.26 <0.0001 <0.0001
_ALFA1
Alpha-1 globulin (%)
2.54
0.39
2.79
0.48 <0.0001 <0.0001
_ALFA2
Alpha-2 globulin (%)
11.06
1.28
11.59
1.46 <0.0001 <0.0001
_BUN
Blood urea nitrogen (mg/dL)
32.98
9.09
39.03 17.24 <0.0001 <0.0001
_C20_5B
Fatty acid C20:5 n-3 weight (mg/L)
20.16
8.93
17.85
6.99 <0.0001 <0.0001
_C20_5C
Fatty acid C20:5 n-3 as % of total fatty acid weight
0.63
0.22
0.56
0.18 <0.0001 <0.0001
_CL24
Creatinine clearance, 24-hr urine (mL/minute)
86.84 30.09
66.91 25.91 <0.0001 <0.0001
_CNCME
MCH concentration (MCHC) (g/dL)
33.95
0.98
33.47
1.15 <0.0001 <0.0001
_CPK
Creatine phosphokinase (U/L)
108.00 89.65
85.68 58.45 <0.0001 <0.0001
_CTX_1
C-terminal telopeptide of type-1 collagen (ng/mL)
0.46
0.23
0.62
0.39 <0.0001 <0.0001
_CYSC
Cystatin C (mg/L)
0.93
0.26
1.16
0.46 <0.0001 <0.0001
_DHEAS
Dehydroepiandrosterone sulfate (µg/dL)
115.68 96.75
72.89 64.01 <0.0001 <0.0001
_ESTDIO
Estradiol via radioimmunoassay (pg/mL)
13.46 17.95
8.90
6.13 <0.0001 <0.0001
_FIBRIN
Fibrinogen (mg/dL)
341.17 73.84
378.87 76.32 <0.0001 <0.0001
_FT4
Free thyroxine, fT4 (ng/dL)
1.42
0.31
1.53
0.45 <0.0001 <0.0001
_GPT
ALT (U/L)
21.19 14.29
17.22
9.37 <0.0001 <0.0001
_GR
Red blood cells (RBC) (n, millions/µL)
4.56
0.41
4.35
0.48 <0.0001 <0.0001
_HOMCYS
Homocysteine via FPIA analysis (µmol/L)
14.59
6.43
17.62
7.69 <0.0001 <0.0001
_IDE
Red cell distribution width (RDW) (%)
13.54
0.95
14.01
1.23 <0.0001 <0.0001
_MMA
Methylmalonic acid, MMA (µmol/L)
0.10
0.03
0.11
0.03 <0.0001 <0.0001
_OM3_MG
Omega-3 plasma fatty acid weight (mg/L)
110.63 41.96
98.98 37.76 <0.0001 <0.0001
_PTH
Parathyroid hormone, two-site immunoradiometric assay (pg/mL)
23.69 17.54
31.58 24.54 <0.0001 <0.0001
_RESIST
Resistin via EIA (ng/mL)
3.78
1.84
4.62
2.57 <0.0001 <0.0001
_TNFAR1
Soluble TNF-a receptor I via quantitative sandwich EIA (pg/mL)
1310.62 578.43
1842.17 1068.12 <0.0001 <0.0001
_UCA
Urinary Ca (mmol/L)
2.43
1.65
1.97
1.55 <0.0001 <0.0001
_UCRE24
24-hour urinary creatinine (mg/24 hours)
1058.67 372.66
825.55 326.16 <0.0001 <0.0001
_IL18
Interleukin-18 via ELISA ultrasensitive using plasma (pg/mL)
388.48 148.94
429.37 175.28
0.0002 0.0003
GFBP3C
IGF binding protein-3, serum, immunoradiometric assay (ng/mL) ***corrected***
4397.72 1104.44
4122.44 1097.82
0.0002 0.0003
_OM6_MG
Omega-6 plasma fatty acid weight (mg/L)
1060.54 234.87
998.91 256.10
0.0003 0.0004
_N_LIN
Lymphocytes (n, K/µL)
1.94
0.65
1.79
0.63
0.0005 0.0007
_TRAIL
TNF-related apoptosis-inducing ligand (pg/mL)
75.80 40.87
69.69 23.55
0.001
0.002
_IL6
Interleukin-6 via ELISA ultrasensitive (pg/mL)
1.76
2.07
3.04
7.1
0.002
0.002
_CORTDH
Cortisol:DHEAS ratio (nmols)
0.28
0.71
0.53
1.81
0.002
0.002
_OM6_3A
Ratio of Omega-6:Omega-3 as % of total fatty acid area
16.38
5.05
17.51
6.06
0.005
0.005
_BCAROT
Beta-carotene via high performance liquid chromatography (µmol/L)
0.43
0.28
0.38
0.23
0.009
0.011
_ATOCRS
Vitamin E alpha tocopherol, high performance liquid chromatography, assay #2 (µmol/L)
33.68
7.32
32.33
8.31
0.011
0.012
_OM6_3M
Ratio of Omega-6:Omega-3 as % of total fatty acid mols
11.52
3.34
12.17
4.11
0.016
0.018
_URICO
Uric acid (mg/dL)
5.03
1.35
5.27
1.65
0.019
0.021
_VGM
Mean corpuscular volume (MCV) (fL)
90.04
4.65
90.76
5.22
0.03
0.031
_CORTIS
Serum cortisol (µg/dL)
13.62
5.00
13.02
4.32
0.039
0.039
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Table XIV. Difference between healthy control and frailty results Model I

Frail.Model1.Feature.codeFrailty Model 1
X_25OH_D
25(OH)-D (25-hydroxyvitamin D) via RIA (nmol/L)
X_ALB
Albumin (%)
X_ATOCRS
Vitamin E alpha tocopherol, high performance liquid chromatography, assay #2 (µmol/L)
X_BUN
Blood urea nitrogen (mg/dL)
X_CL24
Creatinine clearance, 24-hr urine (mL/minute)
X_CNCME
MCH concentration (MCHC) (g/dL)
X_CPK
Creatine phosphokinase (U/L)
X_CTX_1
C-terminal telopeptide of type-1 collagen (ng/mL)
X_CYSC
Cystatin C (mg/L)
X_HOMCYS
Homocysteine via FPIA analysis (µmol/L)
X_IDE
Red cell distribution width (RDW) (%)
X_IL6
Interleukin-6 via ELISA ultrasensitive (pg/mL)
X_OM6_MG
Omega-6 plasma fatty acid weight (mg/L)
X_PTH
Parathyroid hormone, two-site immunoradiometric assay (pg/mL)
X_RESIST
Resistin via EIA (ng/mL)
X_TNFAR1
Soluble TNF-a receptor I via quantitative sandwich EIA (pg/mL)
X_UCRE24
24-hour urinary creatinine (mg/24 hours)
X_CRP_HS
C-reactive protein - high sensitivity (µg/mL)
X_FREETS
Free testosterone (ng/dL), Vermeulen
X_HB
Hemoglobin (g/dL)
X_HCT
Hematocrit (%)
X_IL1RA
Interleukin-1 receptor antagonist via ELISA ultrasensitive (pg/mL)
X_N_NEU
Neutrophils (n, K/µL)
X_P_LIN
Lymphocytes (%)
X_TESTO
Total testosterone (ng/mL)
X_TNFAR2
Soluble TNF-a receptor II via quantitative sandwich EIA (pg/mL)
X_VES
Erythrocyte sedimentation rate (ESR) (mm/hour)
X_DHEAS
Dehydroepiandrosterone sulfate (µg/dL)
X_FOLICG
Folate via RIA (ng/mL)
X_FT4
Free thyroxine, fT4 (ng/dL)
X_P_NEU
Neutrophils (%)
X_SCD14
Soluble CD14 via ELISA (ng/mL)
X_TIGF1
Total insulin-like growth factor-1, serum, immunoradiometric assay (ng/mL)
X_TRAIL
TNF-related apoptosis-inducing ligand (pg/mL)
X_ESRAGE
Endogenous secretory receptor for AGEs (ng/mL)
X_OM6_A
Omega-6 fatty acids as % of total fatty acid area
X_COLLDL
Lipids: LDL cholesterol (mg/dL)
X_UCREAT
Urinary creatinine (mg/dL)
X_OM3_MG
Omega-3 plasma fatty acid weight (mg/L)
X_COLTOT
Lipids: total cholesterol (mg/dL)
X_UCA
Urinary Ca (mmol/L)
X_GB
White blood cells (WBC) (n, K/µL)
X_VITB6G
Vitamin B6 via high performance liquid chromatography (ng/mL)
X_GPT
ALT (U/L)
X_LYCOPN
Lycopene via high performance liquid chromatography (µmol/L)
X_C20_5B
Fatty acid C20:5 n-3 weight (mg/L)
X_RETINL
Retinol via high performance liquid chromatography (µmol/L)
X_UNA
Urinary Na (mmol/L)
X_UCOR24
24-hour urinary cortisol (µg/24 hours)
X_U_PRO
Urine proteins (mg/dL)
X_C24_0B
Fatty acid C24:0 weight (mg/L)
X_C16_0C
Fatty acid C16:0 as % of total fatty acid weight
X_C16_0A
Fatty acid C16:0 as % of total fatty acid area
X_C20_5A
Fatty acid C20:5 n-3 as % of total fatty acid area

Control Mean
54.93
59.18
34.44
33.79
81.09
33.90
104.22
0.47
0.97
14.97
13.62
1.66
1069.54
24.06
3.72
1343.02
1020.45
4.06
2.41
13.99
41.25
142.73
3.59
31.42
2.58
2625.69
17.72
91.21
3.50
1.43
59.52
1724.25
122.04
79.52
0.43
30.16
139.09
73.94
110.92
220.84
2.35
6.01
7.47
20.47
0.71
20.46
1.97
96.75
105.33
0.73
4.66
22.38
24.66
0.47
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SD
Frailty Mean
SD
34.51
43.53 35.76
3.38
57.96
3.73
7.65
32.65
7.39
7.44
37.5 15.92
24.06
70.00 26.43
1.02
33.56
1.05
61.69
86.84 55.12
0.23
0.58
0.35
0.19
1.13
0.42
5.70
17.31
8.12
0.93
13.89
1.16
1.75
2.92
5.74
249.81
1005.32 234.97
19.79
30.54 22.59
1.67
4.36
2.48
429.61
1780.92 979.8
334.7
860.38 323.47
5.99
6.79 11.93
2.22
1.72
1.9
1.25
13.43
1.51
3.23
39.96
3.95
85.5
177.97 159.09
1.18
3.90
1.31
7.87
29.5
8.23
2.09
1.91
1.89
612.55
3053.98 958.87
14.75
25.45 21.55
69.26
75.51 63.29
2.12
3.03
1.88
0.29
1.51
0.41
8.49
61.48
8.52
315.92
1810.47 383.4
54.74
109.52 53.64
54.09
70.44 20.08
0.19
0.48
0.27
4.16
29.17
4.57
35.77
132.56
32.7
35.12
67.37
31.9
44.27
102.85 37.76
40.73
213.53 38.74
1.65
2.04
1.58
1.56
6.29
1.63
6.61
6.09
9.08
11.99
18.43 12.05
0.34
0.65
0.34
9.87
18.95
7.51
0.50
1.88
0.54
46.4
89.89 39.48
52.21
95.94 73.57
7.61
1.92
8.98
4.51
4.05
4.11
2.36
22.72
2.48
2.36
24.99
2.47
0.21
0.44
0.19

Corrected
|t|-test p-value
<0.0001 <0.0001
<0.0001 <0.0001
<0.0001 <0.0001
<0.0001 <0.0001
<0.0001 <0.0001
<0.0001 <0.0001
<0.0001 <0.0001
<0.0001 <0.0001
<0.0001 <0.0001
<0.0001 <0.0001
<0.0001 <0.0001
<0.0001 <0.0001
<0.0001 <0.0001
<0.0001 <0.0001
<0.0001 <0.0001
<0.0001 <0.0001
<0.0001 <0.0001
<0.0001 <0.0001
<0.0001 <0.0001
<0.0001 <0.0001
<0.0001 <0.0001
<0.0001 <0.0001
<0.0001 <0.0001
<0.0001 <0.0001
<0.0001 <0.0001
<0.0001 <0.0001
<0.0001 <0.0001
0.0002
0.0003
0.0002
0.0003
0.0002
0.0003
0.0002
0.0003
0.0002
0.0003
0.0002
0.0003
0.0005
0.0008
0.0005
0.0008
0.0005
0.0008
0.0022
0.0032
0.0023
0.0033
0.003
0.004
0.0031
0.0042
0.0036
0.0047
0.0037
0.0048
0.0057
0.0072
0.0062
0.0076
0.0081
0.0097
0.0088
0.0103
0.0103
0.0118
0.0153
0.0172
0.0231
0.0255
0.0292
0.0315
0.0316
0.0331
0.0319
0.0331
0.0408
0.0416
0.0471
0.0471

Table XV. Difference between healthy control and cognitive frailty Model I
Cognitive Frialty
CogFrail.Model1.Feature.code
Cogntive Frailty Model 1
Control Mean SD
Mean
SD
|t|-test
Corrected p-value
X_25OH_D
25(OH)-D (25-hydroxyvitamin D) via RIA (nmol/L)
52.59
36.24
35.7
29.34
<0.0001
<0.0001
X_ADIPON
Adiponectin via RIA (µg/mL)
13.24
9.5
17.84
12.39
<0.0001
<0.0001
X_ALB
Albumin (%)
58.98
0.38
56.96
4.01
<0.0001
<0.0001
X_ALFA1
Alpha-1 globulin (%)
2.59
0.39
2.86
0.51
<0.0001
<0.0001
X_ALFA2
Alpha-2 globulin (%)
11.21
1.25
11.71
1.55
<0.0001
<0.0001
X_ATOCRS
Vitamin E alpha tocopherol, high performance liquid chromatography, assay #2 (µmol/L)
34.18
7.33
31.05
7.93
<0.0001
<0.0001
X_BUN
Blood urea nitrogen (mg/dL)
37.14
9.44
41.67
19.73
<0.0001
<0.0001
X_C20_5C
Fatty acid C20:5 n-3 as % of total fatty acid weight
0.63
0.23
0.55
0.17
<0.0001
<0.0001
X_CNCME
MCH concentration (MCHC) (g/dL)
33.84
1
33.3
1.11
<0.0001
<0.0001
X_CPK
Creatine phosphokinase (U/L)
99.49
59.53
79.37
54.47
<0.0001
<0.0001
X_CTX_1
C-terminal telopeptide of type-1 collagen (ng/mL)
0.49
0.25
0.68
0.41
<0.0001
<0.0001
X_CYSC
Cystatin C (mg/L)
0.99
0.26
1.26
0.51
<0.0001
<0.0001
X_DHEAS
Dehydroepiandrosterone sulfate (µg/dL)
87.58
67.99
66.59
58.9
<0.0001
<0.0001
X_FIBRIN
Fibrinogen (mg/dL)
351.8
72.83
388.15
80.03
<0.0001
<0.0001
X_HOMCYS
Homocysteine via FPIA analysis (µmol/L)
15.46
6.66
18.84
8.18
<0.0001
<0.0001
X_IDE
Red cell distribution width (RDW) (%)
13.66
0.94
14.15
1.31
<0.0001
<0.0001
X_OM3_MG
Omega-3 plasma fatty acid weight (mg/L)
109.63
42.53
96.43
34.25
<0.0001
<0.0001
X_PTH
Parathyroid hormone, two-site immunoradiometric assay (pg/mL)
25.32
18.84
35.26
28.42
<0.0001
<0.0001
X_RESIST
Resistin via EIA (ng/mL)
3.81
1.86
4.94
2.82
<0.0001
<0.0001
X_TNFAR1
Soluble TNF-a receptor I via quantitative sandwich EIA (pg/mL)
1430.03
579.89
2091.58
82.89
<0.0001
<0.0001
X_TRAIL
TNF-related apoptosis-inducing ligand (pg/mL)
77.35
44.29
65.53
19.93
<0.0001
<0.0001
X_UCRE24
24-hour urinary creatinine (mg/24 hours)
979.14
333.91
767.17
306.4
<0.0001
<0.0001
X_C20_5A
Fatty acid C20:5 n-3 as % of total fatty acid area
0.47
0.21
0.4
0.16
<0.0001
<0.0001
X_COLLDL
Lipids: LDL cholesterol (mg/dL)
138
33.95
127.04
34.78
<0.0001
<0.0001
X_HB
Hemoglobin (g/dL)
13.9
1.29
12.95
1.6
<0.0001
<0.0001
X_OM6_A
Omega-6 fatty acids as % of total fatty acid area
29.98
4.23
28.41
4.77
<0.0001
<0.0001
X_SCD14
Soluble CD14 via ELISA (ng/mL)
1741.7
334.78
1870.97
406.93
<0.0001
<0.0001
X_TESTO
Total testosterone (ng/mL)
2.37
2.06
1.74
1.75
<0.0001
<0.0001
X_TIGF1
Total insulin-like growth factor-1, serum, immunoradiometric assay (ng/mL)
119.35
54.96
101.45
50.44
<0.0001
<0.0001
X_TNFAR2
Soluble TNF-a receptor II via quantitative sandwich EIA (pg/mL)
2709.69
709.84
3362.15
1054.91
<0.0001
<0.0001
X_VES
Erythrocyte sedimentation rate (ESR) (mm/hour)
19.3
16.32
30.9
24.75
<0.0001
<0.0001
X_ALFTOC
Vitamin E alpha tocopherol, high performance liquid chromatography (µmol/L)
30.7
8.31
27.17
8.37
<0.0001
<0.0001
X_OM6_M
Omega-6 fatty acids as % of total fatty acid mols
31.76
4.32
30.18
4.85
<0.0001
<0.0001
X_P_LIN
Lymphocytes (%)
30.92
8.02
28.56
8.17
0.0002
0.0003
X_U_NIT
Urine nitrites
0.1
0.42
0.32
0.71
0.0002
0.0003
X_UCA
Urinary Ca (mmol/L)
2.28
1.64
1.83
1.47
0.0004
0.0006
X_CA
Ca++ (mg/dL)
9.46
0.45
9.32
0.5
0.0004
0.0006
X_IL1RA
Interleukin-1 receptor antagonist via ELISA ultrasensitive (pg/mL)
151.95
111.77
194.04
178.49
0.0011
0.0016
XIGFBP3C
IGF binding protein-3, serum, immunoradiometric assay (ng/mL) ***corrected***
4279.38
1121.16
4009.81
1077.64
0.0018
0.0025
X_CRP_HS
C-reactive protein - high sensitivity (µg/mL)
4.81
8.05
7.91
13.73
0.0018
0.0025
X_FT4
Free thyroxine, fT4 (ng/dL)
1.45
0.31
1.56
0.5
0.002
0.003
X_BCAROT
Beta-carotene via high performance liquid chromatography (µmol/L)
0.43
0.27
0.37
0.24
0.0039
0.0052
X_BETA
Beta globulins (%)
11.94
1.18
12.25
1.55
0.0065
0.0085
X_GB
White blood cells (WBC) (n, K/µL)
6.08
1.55
6.44
1.76
0.007
0.0089
X_V_PIAS
Mean platelet volume (MPV) (fL)
11.14
0.97
10.94
1
0.0079
0.0097
X_C16_0C
Fatty acid C16:0 as % of total fatty acid weight
22.44
2.36
22.98
2.62
0.008
0.0097
X_URICO
Uric acid (mg/dL)
5.13
1.37
5.47
1.76
0.009
0.0107
X_STFRNM
Soluble transferrin receptor (nmol/L)
16.66
5.65
18.3
8.56
0.0097
0.0113
X_AGECML
Advanced glycation endproduct (AGE): Carboxymethyl-lysine (ng/mL)
361.53
105.78
390.73
152.77
0.0107
0.0122
X_C16_0A
Fatty acid C16:0 as % of total fatty acid area
24.42
2.36
25.24
2.61
0.0112
0.0125
X_ALF2M
Alpha-2-macroglobulin (mg/dL)
210.52
68.3
223.74
68.06
0.0122
0.0134
X_CREA
Serum creatinine (mg/dL)
0.92
0.19
0.98
38
0.0217
0.0234
X_U_PRO
Urine proteins (mg/dL)
0.98
7.78
2.8
10.35
0.0333
0.0352
X_C20_0B
Fatty acid C20:0 weight (mg/L)
2.87
2.84
2.52
1.94
0.0412
0.0427
X_INSULN
Plasma insulin via RIA (mIU/L)
11.47
6.05
10.5
6.27
0.0429
0.0437
X_COLHDL
Lipids: HDL cholesterol (mg/dL)
56.27
14.72
53.8
16.43
0.0466
0.0466
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Table XVI. Difference between healthy control and cognitive decline Model II
Cog.Model2.Feature.code
Cognitive Decline Model II
X_25OH_D 25(OH)-D (25-hydroxyvitamin D) via RIA (nmol/L)
X_ADIPON Adiponectin via RIA (µg/mL)
X_ALB
Albumin (%)
X_ALF2M Alpha-2-macroglobulin (mg/dL)
X_ALFA1
Alpha-1 globulin (%)
X_ALFA2
Alpha-2 globulin (%)
X_BETA
Beta globulins (%)
X_BUN
Blood urea nitrogen (mg/dL)
X_C16_0B Fatty acid C16:0 weight (mg/L)
X_C20_5A Fatty acid C20:5 n-3 as % of total fatty acid area
X_C20_5B Fatty acid C20:5 n-3 weight (mg/L)
X_C20_5C Fatty acid C20:5 n-3 as % of total fatty acid weight
X_C24_0C Fatty acid C24:0 as % of total fatty acid weight
X_CA
Ca++ (mg/dL)
X_CL24
Creatinine clearance, 24-hr urine (mL/minute)
X_CNCME MCH concentration (MCHC) (g/dL)
X_CNTME Mean corpuscular hemoglobin (MCH) (pg)
X_CORTDH Cortisol:DHEAS ratio (nmols)
X_CPK
Creatine phosphokinase (U/L)
X_CRP_HS C-reactive protein - high sensitivity (µg/mL)
X_CTX_1
C-terminal telopeptide of type-1 collagen (ng/mL)
X_CYSC
Cystatin C (mg/L)
X_DHEAS Dehydroepiandrosterone sulfate (µg/dL)
X_ESRAGE Endogenous secretory receptor for AGEs (ng/mL)
X_ESTDIO Estradiol via radioimmunoassay (pg/mL)
X_FIBRIN Fibrinogen (mg/dL)
X_FREETS Free testosterone (ng/dL), Vermeulen
X_FT4
Free thyroxine, fT4 (ng/dL)
X_GLU
Blood glucose (mg/dL)
X_GPT
ALT (U/L)
X_GR
Red blood cells (RBC) (n, millions/µL)
X_HB
BL Hemoglobin (g/dL)
X_HCT
BL Hematocrit (%)
X_HOMCYS Homocysteine via FPIA analysis (µmol/L)
X_IDE
Red cell distribution width (RDW) (%)
Interleukin-18 via ELISA ultrasensitive using plasma
X_IL18
(pg/mL)
Interleukin-1 receptor antagonist via ELISA
X_IL1RA
ultrasensitive (pg/mL)
X_IL6
Interleukin-6 via ELISA ultrasensitive (pg/mL)
X_INSULN Plasma insulin via RIA (mIU/L)
X_LP_A
Lipoprotein(a) (mg/dL)
X_MMA
Methylmalonic acid, MMA (µmol/L)
X_N_LIN
Lymphocytes (n, K/µL)
X_NA
Na+ (mEq/L)

Control
Cognitive
TrailA Mean
SD
Mean
60.15 35.34 45.59
12.02 8.69
15.3
60.08 3.24 58.34
198.81 63.42 216.06
2.5
0.38
2.67
10.94 1.24 11.35
11.66 1.24 12.04
32.23 7.68 35.75
NA
NA
NA
0.49 0.21
0.45
20.55 9.62 19.22
0.64 0.24
0.59
0.15 0.13
0.13
9.49 0.44
9.42
92.61 30.4 72.83
34.09 0.94 33.64
30.67 1.74 30.45
0.25 0.58
0.43
113.55 100.7 95.32
3.89 5.78
5.87
0.43
0.2
0.54
0.89
0.2
1.06
124.75 101.28 85.52
0.43 0.21
0.46
14.79 17.95
9.25
334.82 71.84 361.82
3.04 2.98
1.73
1.39 0.29
1.48
91.66 23.24 97.13
21.76 13.91 18.88
4.58 0.39
4.47
14.03 1.28 13.58
41.13 3.28 40.36
13.91 5.44 16.26
13.44 0.89 13.81
NA

NA

NA

Corrected
SD |t|-test p-value TrailB
35.96 <0.0001 <0.0001
11.07 <0.0001 <0.0001
3.47 <0.0001 <0.0001
70.31 <0.0001 <0.0001
0.41 <0.0001 <0.0001
1.31 <0.0001 <0.0001
1.31 <0.0001 <0.0001
12.41 <0.0001 <0.0001
NA
NA
NA
0.18 0.0011 0.0015
7.22 0.0097 0.0112
0.19 0.0011 0.0015
0.14 0.016 0.0176
0.45 0.0093 0.0109
25.51 <0.0001 <0.0001
1.02 <0.0001 <0.0001
1.96 0.0368 0.0385
1.54 0.0118 0.0133
58.92 <0.0001 <0.0001
11.73 0.0004 0.0006
0.3 <0.0001 <0.0001
0.35 <0.0001 <0.0001
70.91 <0.0001 <0.0001
0.22 0.0382 0.0393
6.72 <0.0001 <0.0001
75.38 <0.0001 <0.0001
1.91 <0.0001 <0.0001
0.37 <0.0001 <0.0001
28.81 0.0004 0.0006
11.88 0.0001 0.0001
0.43 <0.0001 <0.0001
1.31 <0.0001 <0.0001
3.5 <0.0001 <0.0001
7.09 <0.0001 <0.0001
1 <0.0001 <0.0001
NA

NA

NA

146.07 101.47 164.11 128.81 0.0078
1.55 1.82
2.47 5.54 0.0002
10.57 6.24 22.45 6.24 0.0161
NA
NA
NA
NA
NA
0.1
0.03
0.11 0.03 0.0012
1.96 0.65
1.85 0.65 0.0007
141.6 2.35 142.045 2.63 0.0019

0.0093
0.0003
0.0176
NA
0.0016
0.001
0.0024
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Control
Mean
65.04
11.26
60.9
192.94
2.46
10.66
11.43
30.77
704.19
NA
NA
NA
0.16
NA
99.97
34.26
NA
0.23
125.29
3.18
0.41
0.84
153.71
NA
18.56
320.51
3.5
1.39
87.99
NA
NA
14.05
NA
13.39
13.33

Cognitive
SD
Mean
35.67 50.09
8.43 14.02
31.4 58.86
59.16 211.62
0.39
2.6
1.25 11.24
1.28 11.97
7.1 34.43
201.01 733.25
NA
NA
NA
NA
NA
NA
0.14
0.14
NA
NA
31.39 79.81
0.93
33.8
NA
NA
0.61
0.45
128.15 99.28
5.17
5
0.19
0.48
0.19
0.99
115.09 91.51
NA
NA
21.94
9.89
70.23 353.39
3.3
2.13
0.27
1.44
18.83 96.84
NA
NA
NA
NA
1.32 13.82
NA
NA
5.22 15.17
0.87 13.68

365.8 143.93
135.45
1.31
9.93
19.14
0.1
2.04
141.51

82.99
1.84
6.45
22.85
0.03
0.65
2.28

SD |t|-test
35.12 <0.0001
10.52 <0.0001
3.32 <0.0001
69.68 <0.0001
0.39 <0.0001
1.25 <0.0001
1.27 <0.0001
10.32 <0.0001
183.76 0.0341
NA
NA
NA
NA
NA
NA
0.13 0.0071
NA
NA
26.95 <0.0001
0.99 <0.0001
NA
NA
1.25 0.0437
58.23 0.0004
8.07 <0.0001
0.26 <0.0001
0.28 <0.0001
72.62 <0.0001
NA
NA
0.34 <0.0001
73.21 <0.0001
2.27 <0.0001
0.33 0.0081
28.52 <0.0001
NA
NA
NA
NA
1.27 0.0056
NA
NA
6.22 <0.0001
0.97 <0.0001

Corrected
p-value
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.0366
NA
NA
NA
0.0085
NA
<0.0001
<0.0001
NA
0.046
0.0006
<0.0001
<0.0001
<0.0001
<0.0001
NA
<0.0001
<0.0001
<0.0001
0.0096
<0.0001
NA
NA
0.007
NA
<0.0001
<0.0001

399.41 151.46 0.0005

0.0007

161.09 130.16 0.0001
1.97 2.18 <0.0001
11.27 6.19 0.0016
22.22 25.42 0.0495
0.11 0.03 0.0002
1.9 0.67 0.0012
141.93 2.52 0.0064

<0.0001
<0.0001
0.0021
0.0495
0.0003
0.0016
0.0079

X_NA

Na+ (mEq/L)

Cog.Model2.Feature.code
Cognitive Decline Model II
X_OM3_A Omega-3 fatty acids as % of total fatty acid area
X_OM3_MG Omega-3 plasma fatty acid weight (mg/L)
Ratio of Omega-6:Omega-3 as % of total fatty acid
X_OM3_W weight
Ratio of Omega-6:Omega-3 as % of total fatty acid
X_OM6_3W weight
X_OM6_A Omega-6 fatty acids as % of total fatty acid area
X_OM6_M Omega-6 fatty acids as % of total fatty acid mols
X_OM6_MG Omega-6 plasma fatty acid weight (mg/L)
X_OM6_W Omega-6 fatty acids as % of total fatty acid weight
X_P_LIN Lymphocytes (%)
X_P_NEU Neutrophils (%)
Parathyroid hormone, two-site immunoradiometric
X_PTH
assay (pg/mL)
X_RESIST Resistin via EIA (ng/mL)
Retinol via high performance liquid chromatography
X_RETINL (µmol/L)
X_SCD14 Soluble CD14 via ELISA (ng/mL)
X_STFRNM Soluble transferrin receptor (nmol/L)
X_TESTO Total testosterone (ng/mL)
Total insulin-like growth factor-1, serum,
X_TIGF1 immunoradiometric assay (ng/mL)
Soluble TNF-a receptor I via quantitative sandwich
X_TNFAR1 EIA (pg/mL)
Soluble TNF-a receptor II via quantitative sandwich
X_TNFAR2 EIA (pg/mL)
X_TSH
Thyroid stimulating hormone, TSH (mIU/L)
X_UCA
Urinary Ca (mmol/L)
X_UCOR24 24-hour urinary cortisol (µg/24 hours)
X_UCORSL Urinary cortisol (µg/mL)
X_UCRE24 24-hour urinary creatinine (mg/24 hours)
X_UCREAT Urinary creatinine (mg/dL)
X_UNA
Urinary Na (mmol/L)
X_VES
Erythrocyte sedimentation rate (ESR) (mm/hour)
X_VGM
Mean corpuscular volume (MCV) (fL)
Vitamin B6 via high performance liquid
X_VITB6G chromatography (ng/mL)
IGF binding protein-3, serum, immunoradiometric
XIGFBP3C assay (ng/mL) ***corrected***

141.6 2.35 142.045 2.63 0.0019 0.0024
141.51 2.28 141.93 2.52 0.0064 0.0079
Control
Cognitive
Corrected
Control
Cognitive
Corrected
TrailA Mean SD Mean SD |t|-test p-value TrailB Mean SD Mean SD |t|-test p-value
2.09 0.62 1.88 0.57 <0.0001 <0.0001
2.16 0.67 1.97 0.59 <0.0001 <0.0001
113.81 43.61 104.23 37.54 <0.0001 <0.0001
NA NA
NA NA NA
NA
3.53

0.98

0.93 <0.0001 <0.0001

3.64

1.04

3.34

0.94 <0.0001 <0.0001

10.34 2.95 10.7 3.19 0.0479 0.0486
31.41 4.39 29.3 4.38 <0.0001 <0.0001
33.15 4.43 331.08 4.46 <0.0001 <0.0001
1082.37 243.69 1028.01 223.72 0.0001 0.0001
34.05 4.43 31.98 4.47 <0.0001 <0.0001
31.98 8.19 30.58 8.03 0.0028 0.0034
59.12 8.81 60.47
8.4 0.0067 0.0081

NA
32.26
33.99
NA
34.89
32.9
58.2

NA
4.3
0.25
NA
4.31
8.42
9.19

NA
30.02
31.8
NA
32.7
31.03
60.03

NA
4.35
4.42
NA
4.43
8.09
8.52

22.24 17.65
3.71 1.72

3.21

27.87 19.24 <0.0001 <0.0001
4.13 2.23 0.0007 0.001

22.33 22.59
3.59 1.65

NA
NA
<0.0001 <0.0001
<0.0001 <0.0001
NA
NA
<0.0001 <0.0001
0.0007 0.001
0.002 0.0026

25.03 14.54 0.0466
3.89 1.95 0.0126

0.0474
0.0143

1.97 0.48 1.88 0.49 0.0005 0.0007
1651.2 339.4 1781.38 335.52 <0.0001 <0.0001
15.98 5.49 16.99 5.48 0.0016 0.002
2.76
2.2 1.94 1.92 <0.0001 <0.0001

1.99 0.47 1.91 0.49 0.0105 0.0121
1595.57 318.07 1733.72 340.59 <0.0001 <0.0001
NA NA
NA NA NA
NA
2.97 2.29 2.17 1.99 <0.0001 <0.0001

147.92 72.25 109.88 51.83 <0.0001 <0.0001

164.2 78.49 121.24 57.78 <0.0001 <0.0001

1200.34 443.28 1594.19 785.34 <0.0001 <0.0001

1101.48 441.51 1418.13 603.9 <0.0001 <0.0001

2416.55
1.66
2.57
108.88
NA
1132.16
81.52
101.12
16.98
89.96

2267.59
NA
2.62
111.52
0.08
1211
88.75
106.71
15.18
89.6

8.32

657.28 2869.39 827.95 <0.0001 <0.0001
2.24 2.36
7 0.0357 0.0379
1.74 2.09 1.47 <0.0001 <0.0001
55.55 100.63 68.22 0.0273 0.0294
NA
NA
NA NA
NA
384.36 884.66 304.86 <0.0001 <0.0001
39.44 67.67 32.17 <0.0001 <0.0001
45.54 92.5 41.92 0.0011 0.0015
15.83 22.82 19.49 <0.0001 <0.0001
4.47 90.49 4.86 0.0492 0.0492
5.57

6.56

6.64 <0.0001 <0.0001

4497.55 1077.25 4229.28 1103.01 <0.0001 <0.0001
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9.34

638.78 2695.09 747.26 <0.0001 <0.0001
NA
NA NA NA
NA
1.56 2.31 1.66 0.0054 0.0069
50.52 102.66 58.56 0.0145 0.0161
0.06 0.07 0.05 0.0201 0.022
383.23 977.63 348.15 <0.0001 <0.0001
42.01 71.27 34.64 <0.0001 <0.0001
46.11 93.3 41.77 <0.0001 <0.0001
14.53 20.48 18.15 <0.0001 <0.0001
4.55 90.21 4.74 0.0458 0.0474
5.91

6.93

6.24 <0.0001 <0.0001

4595.71 993.38 4347.15 1145.3 0.0005

0.0007

Table XVII. Difference between healthy control and frailty Model II

Corrected
Frail.Model2.Feature.code
Frailty Model II
Control Mean SD
Frailty Mean SD
|t|-test p-value
X_ALFTOC
Vitamin E alpha tocopherol, high performance liquid chromatography (µmol/L)
30.99
8.29
29.00
8.46 <0.0001 <0.0001
X_ATOCRS
Vitamin E alpha tocopherol, high performance liquid chromatography, assay #2 (µmol/L)
34.44
7.65
32.65
7.39 <0.0001 <0.0001
X_P_LIN
Lymphocytes (%)
31.42
7.88
29.50
8.23 <0.0001 <0.0001
X_25OH_D
25(OH)-D (25-hydroxyvitamin D) via RIA (nmol/L)
54.93
34.5
43.52 35.77 <0.0001 <0.0001
X_ALFA1
Alpha-1 globulin (%)
2.57
0.36
2.72
0.47 <0.0001 <0.0001
X_BUN
Blood urea nitrogen (mg/dL)
33.79
7.44
37.5 15.92 <0.0001 <0.0001
X_CL24
Creatinine clearance, 24-hr urine (mL/minute)
81.09 24.06
70.00 26.43 <0.0001 <0.0001
X_CNCME
MCH concentration (MCHC) (g/dL)
33.9
1.02
33.56
1.05 <0.0001 <0.0001
X_CPK
Creatine phosphokinase (U/L)
104.23 61.69
86.84 55.12 <0.0001 <0.0001
X_CRP_HS
C-reactive protein - high sensitivity (µg/mL)
4.06
5.99
6.79 11.93 <0.0001 <0.0001
X_CTX_1
C-terminal telopeptide of type-1 collagen (ng/mL)
0.47
0.23
0.58
0.35 <0.0001 <0.0001
X_FREETS
Free testosterone (ng/dL), Vermeulen
2.41
2.22
1.72
1.9 <0.0001 <0.0001
X_GR
Red blood cells (RBC) (n, millions/µL)
4.57
0.38
4.42
0.48 <0.0001 <0.0001
X_HOMCYS
Homocysteine via FPIA analysis (µmol/L)
14.97
5.70
17.32
8.12 <0.0001 <0.0001
X_IL1RA
Interleukin-1 receptor antagonist via ELISA ultrasensitive (pg/mL)
142.73 85.50
177.97 159.09 <0.0001 <0.0001
X_IL6
Interleukin-6 via ELISA ultrasensitive (pg/mL)
1.67
1.75
2.92
5.74 <0.0001 <0.0001
X_N_NEU
Neutrophils (n, K/µL)
3.60
1.18
3.90
1.31 <0.0001 <0.0001
X_OM6_MG
Omega-6 plasma fatty acid weight (mg/L)
1069.54 249.81
1005.32 234.97 <0.0001 <0.0001
X_PTH
Parathyroid hormone, two-site immunoradiometric assay (pg/mL)
24.06 19.79
30.55 22.59 <0.0001 <0.0001
X_RESIST
Resistin via EIA (ng/mL)
3.72
1.67
4.36
2.48 <0.0001 <0.0001
X_TESTO
Total testosterone (ng/mL)
2.58
2.09
1.91
1.89 <0.0001 <0.0001
X_TNFAR1
Soluble TNF-a receptor I via quantitative sandwich EIA (pg/mL)
1343.02 429.62
1780.92 979.8 <0.0001 <0.0001
X_TNFAR2
Soluble TNF-a receptor II via quantitative sandwich EIA (pg/mL)
2625.69 612.55
3053.98 958.87 <0.0001 <0.0001
X_UCRE24
24-hour urinary creatinine (mg/24 hours)
1020.45 334.70
860.38 323.47 <0.0001 <0.0001
X_VES
Erythrocyte sedimentation rate (ESR) (mm/hour)
17.72 14.75
25.45 21.55 <0.0001 <0.0001
X_IL6_EC
IL-6 high-sensitivity ELISA calculated from ELISA ultrasensitive (pg/mL)
3.11
2.00
4.23
2.82 <0.0001 <0.0001
X_ALF2M
Alpha-2-macroglobulin (mg/dL)
205.18 66.26
221.01 69.64 0.0002
0.0003
X_DHEAS
Dehydroepiandrosterone sulfate (µg/dL)
91.21 69.26
75.51
63.3 0.0002
0.0003
X_FOLICG
Folate via RIA (ng/mL)
3.50
2.12
3.03
1.88 0.0002
0.0003
X_FT4
Free thyroxine, fT4 (ng/dL)
1.43
0.30
1.51
0.41 0.0002
0.0003
X_SCD14
Soluble CD14 via ELISA (ng/mL)
1724.25 315.92
1810.47 383.4 0.0002
0.0003
X_TIGF1
Total insulin-like growth factor-1, serum, immunoradiometric assay (ng/mL)
122.04 54.74
109.52 53.63 0.0002
0.0003
X_ESRAGE
Endogenous secretory receptor for AGEs (ng/mL)
0.43
0.19
0.48
0.27 0.0005
0.0008
X_OM6_A
Omega-6 fatty acids as % of total fatty acid area
30.16
4.16
29.17
4.57 0.0005
0.0008
X_TRAIL
TNF-related apoptosis-inducing ligand (pg/mL)
79.52 54.09
70.44 20.08 0.0005
0.0008
X_COLLDL
Lipids: LDL cholesterol (mg/dL)
139.01 35.77
132.56 32.70 0.0022
0.0034
X_OM3_MG
Omega-3 plasma fatty acid weight (mg/L)
110.92 44.27
102.85 37.76 0.0029
0.0043
X_COLTOT
Lipids: total cholesterol (mg/dL)
220.84 40.73
213.53 38.74 0.0031
0.0045
X_UCA
Urinary Ca (mmol/L)
2.35
1.65
2.04
1.58 0.0036
0.0051
X_GB
White blood cells (WBC) (n, K/µL)
6.01
1.56
6.3
1.63 0.0037
0.0051
X_VITB6G
Vitamin B6 via high performance liquid chromatography (ng/mL)
7.47
6.61
6.09
9.08 0.0057
0.0076
X_GPT
ALT (U/L)
20.48 11.99
18.44 12.05 0.0062
0.0081
X_C20_5B
Fatty acid C20:5 n-3 weight (mg/L)
20.46
9.87
18.95
7.51 0.0088
0.0113
X_ADIPON
Adiponectin via RIA (µg/mL)
13.31
9.72
15.05 10.83 0.0094
0.0118
X_OM3_A
Omega-3 fatty acids as % of total fatty acid area
1.99
0.62
1.89
0.59 0.0141
0.0172
X_UNA
Urinary Na (mmol/L)
96.75 46.40
89.89 39.48 0.0153
0.0183
X_URICO
Uric acid (mg/dL)
5.09
1.29
5.30
1.60 0.0175
0.0205
X_UCOR24
24-hour urinary cortisol (µg/24 hours)
105.33 52.21
95.94 73.57 0.0231
0.0265
X_C20_5
Fatty acid C20:5 n-3 cis (eicosapentaenoic, EPA) area
79.94 51.57
73.05 43.36 0.0275
0.0309
X_U_PRO
Urine proteins (mg/dL)
0.73
7.61
1.93
8.98 0.0292
0.0321
X_C24_0B
Fatty acid C24:0 weight (mg/L)
4.65
4.51
4.05
4.11 0.0316
0.0337
X_C16_0C
Fatty acid C16:0 as % of total fatty acid weight
22.38
2.36
22.72
2.48 0.0319
0.0337
X_C16_0A
Fatty acid C16:0 as % of total fatty acid area
24.66
2.36
24.98
2.46 0.0408
0.0423
X_OM3_W
Omega-3 fatty acids as % of total fatty acid weight
3.35
0.97
3.23
0.95 0.0457
0.0465
X_C20_5A
Fatty acid C20:5 n-3 as % of total fatty acid area
0.47
0.22
0.44
0.19 0.0471
0.0471
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Table XVIII. Difference between healthy control and cognitive frailty Model II
Cog.Frail.Model2.Feature.code
Cognitive Frailty Model II
X_25OH_D 25(OH)-D (25-hydroxyvitamin D) via RIA (nmol/L)
X_ADIPON Adiponectin via RIA (µg/mL)
X_ALB
Albumin (%)
X_ALF2M Alpha-2-macroglobulin (mg/dL)
X_ALFA1
Alpha-1 globulin (%)
Vitamin E alpha tocopherol, high performance liquid
X_ALFTOC chromatography (µmol/L)
Vitamin E alpha tocopherol, high performance liquid
X_ATOCRS chromatography, assay #2 (µmol/L)
X_BUN
Blood urea nitrogen (mg/dL)
X_C20_5A Fatty acid C20:5 n-3 as % of total fatty acid area
X_CL24
Creatinine clearance, 24-hr urine (mL/minute)
X_CNCME MCH concentration (MCHC) (g/dL)
X_CORTIS Serum cortisol (µg/dL)
X_CPK
Creatine phosphokinase (U/L)
X_CRP_HS C-reactive protein - high sensitivity (µg/mL)
X_CTX_1
C-terminal telopeptide of type-1 collagen (ng/mL)
X_CYSC
Cystatin C (mg/L)
X_DHEAS
Dehydroepiandrosterone sulfate (µg/dL)
X_ESRAGE Endogenous secretory receptor for AGEs (ng/mL)
X_ESTDIO Estradiol via radioimmunoassay (pg/mL)
X_FIBRIN
Fibrinogen (mg/dL)
X_FOLICG Folate via RIA (ng/mL)
X_FREETS Free testosterone (ng/dL), Vermeulen
X_GLU
Blood glucose (mg/dL)
X_HCT
Hematocrit (%)
X_HOMCYS Homocysteine via FPIA analysis (µmol/L)
Interleukin-18 via ELISA ultrasensitive using plasma
X_IL18
(pg/mL)
Interleukin-1 receptor antagonist via ELISA
X_IL1RA
ultrasensitive (pg/mL)
X_IL6
Interleukin-6 via ELISA ultrasensitive (pg/mL)
Lycopene via high performance liquid
X_LYCOPN chromatography (µmol/L)
X_N_LIN
Lymphocytes (n, K/µL)
X_OM3_A Omega-3 fatty acids as % of total fatty acid area
X_OM6_MG Omega-6 plasma fatty acid weight (mg/L)
X_OM6_W Omega-6 fatty acids as % of total fatty acid weight
X_P_LIN
Lymphocytes (%)
X_P_NEU
Neutrophils (%)
Parathyroid hormone, two-site immunoradiometric
X_PTH
assay (pg/mL)
X_RESIST
Resistin via EIA (ng/mL)
X_SCD14
Soluble CD14 via ELISA (ng/mL)
X_TESTO
Total testosterone (ng/mL)
Total insulin-like growth factor-1, serum,
X_TIGF1
immunoradiometric assay (ng/mL)
Soluble TNF-a receptor I via quantitative sandwich
X_TNFAR1 EIA (pg/mL)
Soluble TNF-a receptor II via quantitative sandwich
X_TNFAR2 EIA (pg/mL)
X_TRAIL
TNF-related apoptosis-inducing ligand (pg/mL)
X_UCA
Urinary Ca (mmol/L)
X_UCOR24 24-hour urinary cortisol (µg/24 hours)
X_UCORSL Urinary cortisol (µg/mL)
X_UCRE24 24-hour urinary creatinine (mg/24 hours)
X_UCREAT Urinary creatinine (mg/dL)
X_UNA
Urinary Na (mmol/L)
X_URICO
Uric acid (mg/dL)
X_VES
Erythrocyte sedimentation rate (ESR) (mm/hour)
Vitamin B6 via high performance liquid
X_VITB6G chromatography (ng/mL)
IGF binding protein-3, serum, immunoradiometric
XIGFBP3C assay (ng/mL) ***corrected***

SD
36.01
9.11
3.34
64.3
0.38

Cognitive
Frailty
Mean
40.97
15.85
58.09
221.07
2.69

SD
34.34
11.71
3.51
73.22
0.43

|t|-test
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001

30.47

8.24

29.01

8.39

0.0092

0.01

33.91
32.61
0.48
88.69
34.01
NA
110.89
4.01
0.44
0.91
116.98
0.43
13.29
339.88
3.41
2.72
NA
41.02
14.16

7.54
7.77
0.20
29.71
1.00
NA
92.60
6.14
0.21
0.21
95.79
0.2
15.99
72.16
2.14
2.80
NA
3.28
5.57

32.86
37.42
0.19
68.68
33.54
NA
88.84
7.11
0.59
1.13
77.99
0.48
9.52
367.95
3.02
1.67
NA
40.06
17.39

7.43
14.90
0.19
25.64
0.96
NA
53.96
14.37
0.35
0.42
67.71
0.25
7.18
78.12
1.70
1.92
NA
3.64
7.78

0.0367
<0.0001
0.027
<0.0001
<0.0001
NA
<0.0001
0.0004
<0.0001
<0.0001
<0.0001
0.0077
<0.0001
<0.0001
0.0013
<0.0001
NA
<0.0001
<0.0001

386.20 149.66

411.61

156.28

146.60
1.57

97.39
1.81

177.16
3.14

154.61
7.22

0.71
0.34
1.95
0.64
2.04
0.62
1069.85 241.60
33.57
4.45
31.96
8.07
59.15
8.64
22.68 16.32
3.75
1.87
1670.14 331.90
2.57
2.17

Control
TrailA Mean
57.82
12.66
59.71
201.68
2.53

139.07

SD
33.73
9.13
3.27
61.88
0.39

Cognitive
Frailty
Mean
47.92
14.66
58.52
223.54
2.64

SD
40.02
11.45
3.45
74.06
0.43

NA

NA

NA

NA

NA

NA

0.0367
<0.0001
0.0275
<0.0001
<0.0001
NA
<0.0001
0.0005
<0.0001
<0.0001
<0.0001
0.0083
<0.0001
<0.0001
0.0017
<0.0001
NA
<0.0001
<0.0001

NA
32.12
NA
9.48
34.07
13.67
115.10
3.77
0.43
0.88
125.8
0.43
14.30
334.56
3.43
2.95
92.18
41.07
13.88

NA
7.20
NA
30.34
1.00
5.06
99.11
6.02
0.20
0.19
100.15
0.18
17.34
73.08
2.14
2.96
24.40
3.23
5.59

NA
0.27
NA
74.67
33.67
12.73
91.46
5.83
0.53
1.07
80.97
0.48
9.35
360.54
3.07
1.74
97.77
40.51
16.17

NA
13.06
NA
25.66
0.96
4.37
54.64
9.44
0.31
0.35
67.13
0.27
6.52
72.38
1.91
1.89
29.05
3.48
6.47

NA
<0.0001
NA
<0.0001
<0.0001
0.0026
<0.0001
0.0004
<0.0001
<0.0001
<0.0001
0.0086
<0.0001
<0.0001
0.0078
<0.0001
0.0028
0.0147
<0.0001

NA
<0.0001
NA
<0.0001
<0.0001
0.0033
<0.0001
0.0006
<0.0001
<0.0001
<0.0001
0.0094
<0.0001
<0.0001
0.0087
<0.0001
0.0034
0.0153
<0.0001

0.0146

0.0154

382.19

150.56

402.02

147.03

0.0478

0.0478

0.0015
0.0003

0.0019
0.0004

142.80
1.46

95.94
1.77

174.54
2.42

153.13 0.0007
2.57 <0.0001

0.001
<0.0001

0.65
1.83
1.88
1022.35
31.76
29.53
61.46

0.31 0.0042
0.67 0.0073
0.56 0.0002
216.50 0.0024
4.64 <0.0001
8.13 <0.0001
8.47 <0.0001

0.005
0.0085
0.0003
0.0029
<0.0001
<0.0001
<0.0001

NA
1.98
2.07
1086.09
33.93
32.45
58.64

NA
NA
0.65
1.87
0.63
1.96
239.82 1034.56
4.42
32.32
8.16
29.87
8.83
61.19

NA
NA
0.69 0.0184
0.60 0.0049
223.86 0.0016
4.52 <0.0001
8.16 <0.0001
8.42 <0.0001

NA
0.0188
0.0056
0.0021
<0.0001
<0.0001
<0.0001

31.12
4.33
1824.72
1.85

23.23
2.19
386.26
1.87

<0.0001
<0.0001
<0.0001
<0.0001

<0.0001
<0.0001
<0.0001
<0.0001

22.36
3.67
1653.78
2.68

17.44
28.13
1.66
4.05
323.41 1760.93
2.20
1.87

17.47 <0.0001
2.23 0.0094
361.97 <0.0001
1.84 <0.0001

<0.0001
0.01
<0.0001
<0.0001

113.21

55.61 <0.0001

<0.0001

Corrected
Control
p-value TrailB Mean
<0.0001
58.33
<0.0001
12.41
<0.0001
59.99
<0.0001
197.37
<0.0001
2.51

69.69

106.54

49.24 <0.0001

<0.0001

145.42

1248.81 471.88

1763.25

914.92 <0.0001

<0.0001

1191.01

432.04 1592.49

741.76 <0.0001

<0.0001

2473.75 654.70
76.51 42.76
2.50
1.74
108.98 32.17
1082.84 374.84
1082.84 374.84
78.09 38.10
99.50 45.59
4.98
1.28
17.59 15.96

3059.1
71.47
1.90
93.34
833.83
833.83
66.78
90.34
5.22
25.67

924.41
19.74
1.18
57.87
294.48
294.48
32.12
38.51
1.56
21.42

<0.0001
0.0064
<0.0001
0.0001
<0.0001
<0.0001
<0.0001
0.0014
0.0148
<0.0001

<0.0001
0.0074
<0.0001
0.0001
<0.0001
<0.0001
<0.0001
0.0018
0.0154
<0.0001

2399.93
NA
2.52
109.66
1119.54
1119.54
80.74
101.58
4.93
16.67

623.03 2903.60
NA
NA
1.63
2.15
50.09
96.01
381.66 902.09
381.66 902.09
39.52
68.38
44.78
88.47
1.29
5.19
14.84
23.32

862.17
NA
1.64
67.41
314.87
314.87
33.02
39.39
1.36
20.66

<0.0001
NA
0.0001
0.0018
<0.0001
<0.0001
<0.0001
<0.0001
0.0036
<0.0001

<0.0001
NA
0.0001
0.0023
<0.0001
<0.0001
<0.0001
<0.0001
0.0042
<0.0001

5.47 <0.0001

<0.0001

8.48

5.79 <0.0001

<0.0001

8.12

6.21

4452.55 1077.41

5.75

4158.20 1124.84
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0.0001

0.0001

71.16

Corrected
|t|-test p-value
<0.0001 <0.0001
0.0028
0.0034
<0.0001 <0.0001
<0.0001 <0.0001
<0.0001 <0.0001

6.28

6.08

4517.72 1060.85 4238.12 1166.19

0.0004

0.0006
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Brand Name
Theralen™
Spasmonal™
Xanax™
Abilify™
Saphris™
Tenormin™
Wellbutrin™, Zyban™
Capoten™
Zyrtec™
Diuril™, Hygroton™
Tagamet™
Librax™
Tranxene™
Contin™
Colcrys™
Clarinex™
Valium™
Lanoxin™
Persantine™
Norpace™
Duragesic™, Actiq™
Lasix™
Luvox™
Haldol™
Apresoline™
Cortef™, Cortaid™
Fanapt™
Isordil™, Ismo™
Xyzal™
Immodium™, others
Claritin™
Lopressor™, Toprol™
MS Contin™, Avinza™
Procardia™, Adalat™
Invega™
Deltasone™, Sterapred™
Quinaglute™
Zantac™
Risperdal™
Theodur™, Uniphyl™
Desyrel™
Dyrenium™
Effexor™
Coumadin™

Alprazolam

Aripiprazole
Asenapine
Atenolol
Bupropion
Captopril
Cetirizine
Chlorthalidone
Cimetidine
Clidinium
Clorazepate
Codeine
Colchicine
Desloratadine
Diazepam
Digoxin
Dipyridamole
Disopyramide
Fentanyl
Furosemide
Fluvoxamine
Haloperidol
Hydralazine
Hydrocortisone
Iloperidone
Isosorbide
Levocetirizine
Loperamide
Loratadine
Metoprolol
Morphine
Nifedipine
Paliperidone
Prednisone
Quinidine
Ranitidine
Risperidone
Theophylline
Trazodone
Triamterene
Venlafaxine
Warfarin

Drugs with ACB Score of 1

Generic Name
Alimemazine
Alverine
Symmetrel™
Multiple
Tegretol™
Flexeril™
Periactin™
Loxitane™
Demerol™
Levoprome™
Moban™
Nefogesic™
Trileptal™
Orap™

Amantadine
Belladonna
Carbamazepine
Cyclobenzaprine
Cyproheptadine
Loxapine
Meperidine
Methotrimeprazine
Molindone
Nefopam
Oxcarbazepine
Pimozide
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Notes:
t Each definite anticholinergic may increase the risk of
cognitive impairment by 46% over 6 years. 3
t For each on point increase in the ACB total score, a
decline in MMSE score of 0.33 points over 2 years has
been suggested. 4
t Additionally, each one point increase in the ACB total
score has been correlated with a 26% increase in the
risk of death. 4

Numerical Scoring:
t Add the score contributed to each selected medication
in each scoring category
t Add the number of possible or definite Anticholinergic
medications

Categorical Scoring:
t Possible anticholinergics include those listed with a
score of 1; Definite anticholinergics include those
listed with a score of 2 or 3

Brand Name

Drugs with ACB Score of 2
Generic Name
Brand Name
Elavil™
Asendin™
Sal-Tropine™
Cogentin™
Dimetapp™
Histex™, Carbihist™
Chlor-Trimeton™
Thorazine™
Tavist™
Anafranil™
Clozaril™
Enablex™
Norpramin™
Bentyl™
Dramamine™, others
Benadryl™, others
Sinequan™
Unisom™, others
Toviaz™
Urispas™
Atarax™, Vistaril™
Anaspaz™, Levsin™
Tofranil™
Antivert™
Robaxin™
Pamelor™
Zyprexa™
Norflex™
Ditropan™
Paxil™
Trilafon™
Phenergan™
Pro-Banthine™
Detrunorm™
Seroquel™
Transderm Scop™
Vesicare™
Mellaril™
Detrol™
Stelazine™
Artane™
Surmontil™
Sanctura™

Drugs with ACB Score of 3
Generic Name
Amitriptyline
Amoxapine
Atropine
Benztropine
Brompheniramine
Carbinoxamine
Chlorpheniramine
Chlorpromazine
Clemastine
Clomipramine
Clozapine
Darifenacin
Desipramine
Dicyclomine
Dimenhydrinate
Diphenhydramine
Doxepin
Doxylamine
Fesoterodine
Flavoxate
Hydroxyzine
Hyoscyamine
Imipramine
Meclizine
Methocarbamol
Nortriptyline
Olanzapine
Orphenadrine
Oxybutynin
Paroxetine
Perphenazine
Promethazine
Propantheline
Propiverine
Quetiapine
Scopolamine
Solifenacin
Thioridazine
Tolterodine
Trifluoperazine
Trihexyphenidyl
Trimipramine
Trospium

MANUSCRIPT 4: Anticholinergic Burden Scale
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Anticholinergic Burden Scale script with instructions for research assistant and/or participant
permission to use instrument from author

Anticholinergic Burden Scale Permission
We do not have a formal letter. You can use the following email:
You have permission to use the Anticholinergic Cognitive Burden Scale for your dissertation
related work including both research and educational purposes.
Malaz
Malaz Boustani, MD, MPH
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TO:
CC:
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Lana Sargent

FROM: VCU IRB Panel B
RE:
Patricia Slattum ; IRB HM20006652 Predicting cognitive frailty: a population modeling study
On 2/3/2016 the referenced research study qualified for exemption according to 45 CFR 46.101(b), category
4.
The information found in the electronic version of this study’s smart form and uploaded documents now
represents the currently approved study, documents, and HIPAA pathway (if applicable). You may access this
information by clicking the Study Number above.
If you have any questions, please contact the Office of Research Subjects Protection (ORSP) or
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Attachment – Conditions of Exempt Approval
Conditions of Exempt Approval:
In order to comply with federal regulations, industry standards, and the terms of this approval,
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2. Provide non-English speaking patients with a translation of the approved Consent
Form in the research participant's first language. The Panel must approve the
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3. The following changes to the protocol must be submitted to the IRB panel for review
and approval before the changes are instituted. Changes that do not meet these criteria
do not have to be submitted to the IRB. If there is a question about whether a change
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182

TRAINING AIM DOCUMENT

Bioinformatics 101 Seminar Series

Certificate of Completion
Presented by the C. Kenneth and Dianne Wright Center for Clinical and
Translational Research and Vice President for Research and Innovations
Is Awarded To

Lana Sargent

For the successful completion of all requirements

November 16, 2016
F. Gerard Moeller, M.D.
Director, C. Kenneth and Dianne Wright Center for
Clinical and Translation Research, Associate Vice
President for Clinical Research

Krzysztof Cios, Ph.D., D.Sc., MBA
Director, Enterprise Informatics
Director, Biomedical Informatics Core

183

